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All eukaryotic cells are surrounded by a cellular membrane that functions as a barrier between 
subcellular compartments and between the cell and its environment. In addition to proteins, they 
are composed by three different set of lipids: glycerolipids, sphingolipids and sterols.  
Glycerolipids are the major components of cell membranes and they are produced using 
phosphatidic acid (PtdOH) as a central precursor. Instead, sphingolipids (SLs), the minor cell 
components, have sphingosine as basic building block; the additions of oligosaccharides to 
sphingosine giving rise glycosphingolipids (GSLs). SLs and GSLs are not distribute 
homogeneously in the outer plasma membrane. They form small, heterogeneous, highly dynamic, 
sterol- and sphingolipid-enriched domains, called “lipid rafts”; in these semiordered lipid 
microdomains, SLs are involved in cell adhesion/recognition processes and signal transduction 
pathway. The organ with the highest enrichment in lipids such as cholesterol e glycosphingolipids, 
is the brain. Myelin, the fatty white substance that surrounds the axon of nerve cells, is 
characterized by a high lipid-to-protein ratio, where lipids representing 80% of its dry weight. The 
myelin membrane contains a high level of two galactosphingolipids, galactosylceramide (GalCer) 
and 3-O-sulfogalactosylceramide (sulfatide), account for about 20 and 5 % of myelin lipids 
respectively.  The specific roles of GalCer and sulfatide seem to be linked to their ability to form 
and to stabilize specific lateral domains in the membrane of myelin forming-cells and in the myelin 
sheath, that regulate the correct sorting, trafficking, co-clustering and lateral distribution of the 
major myelin proteins. Recent reports have suggested that some of the myelin-specific lipids may 
be key contributors to the pathogenic mechanism of multiple sclerosis (MS), the most common 
demyelinating disease in the CNS. Individuals with MS disease are reported to have different 
myelin lipid compositions and elevated levels of anti-sulfatide Ab in biological fluids compared 
with healthy individuals. On the other hand, anti-myelin antibodies might represent an important 
immunological tool for the treatment of neurological diseases involving myelin lesions. In 
particular, it has been shown that human monoclonal antibodies that bind myelin and 
oligodendrocytes (OLs), as rHIgM22, can initiate dramatic increase in remyelination in animal 
models of demyelination. Nowadays, the exact mechanism of action of rHIgM22 remains to be 
elucidated, but some evidence suggest that the mechanism is correlated with the organization of 
lipid rafts on the surface of myelin and OLs.  
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The experiments described in this thesis were aimed at the individuation of the molecular target(s) 
of the antibody and at the characterization of its membrane microenvironment, in order to better 
understand the characteristics of rHIgM22 and its remyelinating activity. 
The binding of rHIgM22 to purified lipids and to lipid extracts from various sources were tested 
using TLC immunostaining assays and SPR assays. The results obtained show that rHIgM22 binds 
to sulfatide, and, to a lesser extent, to lysosulfatide in vitro, while it does not bind to other myelin 
sphingolipids. The binding affinity for both sulfatide and its deacylated derivate is low, even if the 
binding is specific. On the other hand, our data shows that the binding affinity of rHIgM22 for 
sulfatide can be modulated by the presence of other lipids suggesting a possible role of the 
membrane microenvironment in the recognition of the antigen by rHIgM22. In addition, rHIgM22 
also reacts with phosphatidic acid, phosphatidylinositol (PI) and phosphatidylserine (PS).  
To verify whether rHIgM22 can bind sulfatide or other lipids, the binding of rHIgM22 was tested 
not only to purified lipids, but also to partially purified lipid extracts obtained from wild type, ASM 
(-/-), CST (+/-) and CST (-/-) mice brains, mouse mixed glial cells (MGC), mouse astrocytes, rat 
rHIgM22+ OLs, rat microglia, and mouse myelin. In TLC immunostaining experiments for 
aqueous phases, we observed rHIgM22-immunoreactive bands co-migrating with the pure sulfatide 
standard and, unexpectedly, a second rHIgM22-immunoreactive band migrating below sulfated, 
co-migrating with the pure phosphatidylinositol and phosphatidylserine standard, confirming the 
TLC immunostraining data to purified lipids. The identity of phospholipid species has been 
confirmed by ESI mass spectrometry experiments; they show that phosphatidylinositol was an 
18:0/20:4-PI and phosphatidylserine was 18:0/22:6-PS and 18:0/18:1-PS. In addition, MS analysis 
for the fractions enriched in sulfatide, shows that rHIgM22 can bind different sulfated species 
suggesting that this binding is not fatty acid species-specific for the sulfatide. 
All these data suggest that not only sulfatide, but also other membrane lipids might play a role in 
the binding of rHIgM22 to OLs or to other cell types. Moreover, the antigen recognized by 
rHIgM22 could be associated with plasma membrane lipid rafts in these cells and this target could 
be including in a multimolecular complex. The identification of the binding target(s) of a rHIgM22, 
and the characterization of their membrane microenvironment, could greatly contribute to the 
elucidation of the signaling mechanisms underlying the remyelination promoting activity of this 
antibody and also of those involved in MS etiology, allowing to define new potential therapeutic 
strategies. 
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Aq. Ph. Aqueous phase 
CGT UDP-galactose:ceramide galactosyltransferase 
CNS Central nervous system 
CST 3’-phosphoadenosine-5’-phosphosulfate:cerebroside sulfotransferase 
EAE Experimental autoimmune encephalomyelitis  
ESI-MS Electrospray ionisation mass spectrometry 
GalCer Galactosylceramide 
GlcCer Glucosylceramide 
GSLs Glycosphingolipids 
LacCer Lactosylceramide 
MS Mass Spectrometry 
MS  Multiple sclerosis 
OLs Mature oligodendrocytes  
OPCs Oligodendrocyte progenitor cells  
Or. Ph. Organic phase 
PDGF!R Platelet-derived growth factor receptor alpha  
PtdCho - PC Phosphatidylcholine 
PtdEtn - PE Phosphatidylethanolamine 
PtdIns - PI Phosphatidylinositol  
PtdOH - PA Phosphatidic acid  
PtdSer - PS Phosphatidylserine 
rHIgM22 Recombinant human Immunoglobulin M22  
S1P  Sphingosine-1-phosphate  
SK1 Sphingosine kinase 1 
SK2 Sphingosine kinase 2 
SLs Sphingolipids 
SM Sphingomyelin 
SPR Surface plasmon resonance 
Sulfatide 3-O-sulfogalactosylceramide  
TLC Thin layer chromatography 
TMEV Theiler’s murine encephalomyelitis virus 
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All eukaryotic cells are surrounded by a cellular membrane that functions as a barrier between 
subcellular compartments and between the cell and its environment [1]. The basic structure of all 
biological membranes is biomolecular leaf arrangement of lipids, in which the amphoteric lipids 
and cholesterol are oriented so that the hydrophobic portions of the molecules interact, minimizing 
their contact with water or other polar group, and the polar head groups of the lipids are at the 
interface with the aqueous environment. In 1972 Singer and Nicholson introduced the “fluid mosaic 
model” to explain the organization and structure of proteins and lipids that constitute the biological 
membranes. In this model, proteins are actually immersed in a lipid fluid bilayer while others are 
attached either to the inner or the outer surface of the membrane [2]. Cellular membranes are 
formed from a different set of lipids, present in various amounts and proportions. Glycerolipids, 
sphingolipids and sterols are the major classes of lipids that constituted biological membrane and 
there is an asymmetric distribution of these lipid components across them [3].  
 
Glycerolipids 
Glycerolipids are a classes of lipids that have as basic building block the 1,2-diacylglycerol 3-
phosphate (PtdOH, PA or  phosphatidic acid), which has a fatty acyl or alkyl group at the sn-1, 
fatty acyl groups at the sn-2 positions and a characteristic phosphate ester group at the sn-3 position 
of glycerol [4]. Fatty acids in sn-1 are usually saturated, whereas in sn-2 are unsaturated. The 
glycerophospholipid classes are defined based on the substituent at the phosphate ester group at 
sn-3 position of PtdOH: choline (PtdCho or PC), ethanolamine (PtdEtn or PE), serine (PtdSer or 
PS) and phosphatidylinositol (PtdIns or PI). The membranes contain also the plasmalogens (PlsCho 
and PlsEtn), glycerophospholipids containing vinyl-ether linkages and enriched in polyunsaturated 
fatty acids at the sn-2 position [5].  
Glycerophospholipids are amphipathic molecules characterized by a polar (head group) and 
nonpolar ends (tail). The polar end is charged due to the ionization of the phosphate group and 
nitrogenous base, instead the nonpolar tail (fatty acid acyl chains) are hydrophobic and tend to 
aggregate in an aqueous environment (Fig. 1). Physicochemical characteristics of membranes 
depending by variations in the head group, length of the phospholipid acyl chains and the degree 
of saturation of them. In fact, there is diversity in the fatty-acyl species because of differences in 
chain length and degree of unsaturation of the esterified fatty acid and in the distribution of them 
in the asymmetric bilayer.  
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Figure 1. Common glycerophospholipids structure 
 
Glycerolipids metabolism 
PtdOH is the precursor of all glycerophospholipids. It consists of glycerol-3-phosphate with long-
chain fatty acids esterified at the sn -1 and sn -2 positions and the glycerophospholipid classes are 
defined based on the substituent at the sn-3 position. Apart from phosphotidylinositols, 
phospholipids are synthesised on the cytoplasmic leaflet of the endoplasmatic reticulum and to the 
lesser extent in the Golgi complex and inside mitochondria.  
PtdCho and PtdEtn are synthesized mainly via Kennedy cycle [5]. This pathway involves three 
enzymic steps: (1) choline or ethanolamine kinases, localized in cytosol; (2) choline or 
ethanolamine phosphate cytidylyltransferases (PCCT and PECT), distributed between cytosol and 
membrane; (3) CDP-choline or CDP-ethanolamine 1,2-diacylglycerol choline or ethanolamine 
phosphotransferase, integral membrane proteins predominantly present in endoplasmic reticulurn 
[6].   The first committed step of PtdCho and PtdEtn synthesis is base phosphorylation by choline 
or ethanolamine kinase to form phosphocoline and phosphoethanolamine. This is followed by the 
incorporation of CTP (cytidine triphosphate) to produce CDP-choline or CDP- ethanolamine by 
PCCT and PECT, respectively. In final step, choline and ethanolamine phosphotransferases 
catalyze the transfer of phosphocholine or phosphoethanolamine to 1,2-diacyIglycerol from CDP-
choline or CDP-effimolamine, with the release of CMP. PtdCho is also synthesized by the repeated 
methylation of PtdEtn with S-adenosylmethionine, reaction catalyzed by PtdEtn N-
methyltransferase in endoplasmic reticulum and mitochondria [5].  
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PtdSer is synthesized by base-exchange between PtdEtn or PtdCho with serine, where the 
phosphodiester bond of PtdEtn or PtdCho is attacked by the hydroxyl group of serine. The reaction 
is catalyzed by phosphatidylserine synthase I and II localized in endoplasmic reticulum and 
stimulated by Ca2+. The de novo synthesis of Ptdlns start with the biosynthesis of CDP-
diacylglycerol by CDP-diacylglycerol synthase localized in endoplasmic reticulum. This is 
followed by the reaction between CDP-diacylglycerol and inositol by phosphatidylinositol 
synthase [7]. PtdIns can be synthesized also by an exchange reaction in which, in the presence of 
manganese, free myoinositol is incorporated into phosphatidylinositol [8].  
PtdIns is the only phospholipid able to undergo reversible and transient changes at its head-group 
with phosphorylation on position 3,4 and/or 5. This yields seven different phosphorylated forms of 
PtdIns:  PtdIns-4-P, Ptdlns- 4,5-P2, PtdIns-3-P, PtdIns-3,4-P2, and PtdIns-3,4,5- P3.The most 
abundant of these are PtdIns-4-P and PtdIns-4,5-P2inmammalian cells [9]. In addition, CDP-
diacylglycerol is the direct precursor for phosphatidylglycerol (PtdGro) and cardiolipin (di-
PtdGro) [10].  
 
Figure 2. Biosynthesis of glycerophospholipids in brain. Adapted from Farooqui et al. 2000.  
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Biological functions of Glycerolipids 
Glycerolipids are a structurally heterogeneous group of lipids that play key structural and 
functional roles in bacterial, plant, and animal membranes. The role of these lipids in cellular 
biochemistry is only partly clarified, but it is clear them contribution to the cellular homeostasis. 
They are involved in the membrane structuring and curvature changing, cellular growth, protein 
recruitment, signal transduction pathways.  
Phospholipids in membranes constituted barriers to protect the cell and for the organelles within 
those cells. Tougher proteins, phospholipids contribute to the membrane curvature; depending 
on their biochemical structure, some phospholipids induce negative curvature of a membrane 
while others induce a positive one [11].  In cellular plasma membrane, the lipid components are 
asymmetric dispersed and this distribution is not randomly. In general, the external leaflet is 
dominated by PtdCho, whereas Ptdlns is mostly restricted to the cytoplasmic leaflet (Fig. 3) [12]. 
Although migration of lipids across the bilayer is a slow mechanism, phospholipids are 
translocated often by special proteins such as flippases, floppases and scramblases [13].  
 
 
 
Figure 3. Lipid composition varies across the two leaflets of the same membrane. Adapted from 
Lehninger principles of biochemistry.  
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Phosphatidic acid (PtdOH) is the most basic phospholipid and serves as a precursor to other 
glycerophospholipids and due to its conical shape it is involved in curving of membranes [14]. 
Conversion of PtdOH to diacyl-glycerol, however, is also important for regulatory aspects because 
diacylglycerol can serve as a lipid second messenger [15] and as a mediator of vesicle formation 
[16]. Lyso-PtdOH is a naturally occurring phospholipid with hormone and growth factor-like 
activities. Lyso-PtdOH acts as a signaling molecule that is rapidly produced and released by 
activated cells. Lyso-PtdOH added extracellularly binds to specific receptors of target cells and 
stimulates platelet aggregation, smooth muscle contraction, induction of neuronal shape changes 
and leads to cell proliferation [10]. In addition, PtdOH inhibits mitochondrial division and 
stimulates mitochondrial outer membrane fusion [17] and it binds to the Rac protein [18].  
 
Phosphatidylcholine (PtdCho) is an ion known as a zwitterion, has a cylinder shape and is the 
major component of biological membranes, comprising 45-55% of the total lipids [19]. 
Nonetheless, it was reported to be involved in signal transduction events, serving as a substrate for 
the phospholipases to generate signal messengers: it is hydrolysed to release DAG, 
lysophosphatidylcholine, PtdOH (by phospholipase D) and arachidonic acid (by phospholipase 
A2). In neurons, PC can be additionally cleaved by phospholipase B, yielding one 
glycerophosphocholine molecule and two free fatty acids [19]. In addition, PtdCho can be 
converted to sphingomyelins by SM synthase [20] 
 
Phosphatidylethanolamine (PtdEtn) is also a zwitterionic lipid that constituted 15 – 25% of the 
phospholipids [21]. Due to a small size of the head group respect to PtdCho, PE adopts a moderately 
conical shape and induces a negative curvature to the membrane [22].  It is enriched in the inner 
membrane leaflet and it is translocated by across the membrane by the aminophospholipid flippases 
[23]. In addition to its structural role in membranes PtdEtn has multiple important cellular functions 
that were until recently unrecognized. PtdEtn have an important role in the phospholipid 
metabolism, being a substrate for almost all other phospholipids. For example, phosphatidylserine 
synthase 2 (PSS2) makes PtdSer out of PtdEtn at the ER [24]. PtdEtn is also the donor of the 
ethanolamine moiety that covalently modifies several proteins [22] and it is the substrate for the 
hepatic enzyme PE N-methyltransferase [25] that provides approximately one third of the PC in 
the liver. PtdEtn seems to have an important role in the heart since a decreased PE content of 
cardiac myocytes causes cell damage after ischemia, and a tered asymmetrical transbilayer 
distribution of PE in sarcolemmal membranes disrupts these membranes [26]. In the final steps of 
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autophagy, it is used for attachment to LC3 and for autophagosome formation [27, 28], so it is an 
important autophagy marker.  
 
Cardiolipin (di-PtdGro) is a cone-shaped phospholipid dimer and is the chief non-bilayer 
phospholipid found in mitochondria, which are the only organelles to make this lipid [29]. Di-
PtdGro have a head group (glycerol) that is esterified to two phosphatidylglyceride backbone 
fragments rather than one, resulting in a cone-shaped phospholipid dimer.  
It is the chief non-bilayer phospholipid found in mitochondria, which are the only organelles to 
make this lipid and it is almost exclusively associated with the inner mitochondrial membrane.  
This exclusivity association between di-PtdGro and mitochondria indicates an important role for 
PtdGro in mitochondrial bioenergetic processes. Di-PtdGro been shown to interact with a number 
of proteins, including the respiratory chain complexes, substrate carrier proteins and with a large 
number of innermitochondrial membrane (IMM) proteins, enzymes and metabolitecarriers [30].  
Moreover, cardiolipin is involved in different stages of the mitochondrial apoptotic process and in 
mitochondrial membrane dynamics [31]. 
 
Phosphatidylserine (PtdSer), that makes up 2–10% of the total cellular phospholipid content,  have 
a phosphoserine head-group which make him a anionic amino-phospholipid [32].  PtdSer has 
important signaling functions both inside and outside of the cell but it is not symmetrically 
distributed across the two leaflets of the membrane bilayer. It is normally highly enriched in the 
inner leaflet of the plasma membrane, while PtdCho and sphingomyelin, are enriched in the outer 
leaflet [33]. The start point of several important biological processes causes a redistribution of PS 
from the inner to the outer, surface of the plasma membrane. For example, during the blood-clotting 
cascade, the transbilayer asymmetry of PtdSer in the plasma membrane of activated platelets is 
markedly altered so that PtdSer becomes exposed on the cell surface [34, 35]. During sperm 
maturation, the asymmetric distribution of PtdSer in the plasma membrane changes and PtdSer 
becomes exposed on the surface of the sperm [36]. The well-characterized process where there is 
a transbilayer movement of PtdSer from the inner to the outer leaflet is during the early stages of 
apoptosis: the exposure of PtdSer on the surface of apoptotic cells ("eat me" signal) has been 
identified as both an early event in apoptosis and a prerequisite for engulfment of these cells by 
phagocytic cells [37-40]. In addition, the exposure of PS on the surface of red blood cells serves as 
a signal for eryptosis [41]. Furthermore, lyso-PtdSer (PS hydrolysis product) is exposed on the 
surface of activated and dying neutrophils thus initiating the clearance of these cells during acute 
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inflammation [42]. PtdSer has not only extracellular functions, but it has been demonstrated also 
its participation in many intracellular processes. For example, PtdSer is the precursor of PtdEtn via 
the mitochondrial enzyme PtdSer decarboxylase [43]. Although PS represents a minor 
phospholipid in mammalian cells, it is required for many fundamental cellular processes. The 
essential role of PS in mammalian cells was highlighted by the observation that mice in which PS 
synthesis was completely eliminated did not survive [44].  
 
PtdIns, also called monophosphoinositide, is an anionic lipid that comprises 10 – 15% of the 
cellular phospholipids. It is present in various organelles and, like the aminophospholipids, it is 
enriched in the inner leaflet of the plasmalemma than in the outer leaflet [12, 45]. PtdIns is the 
unique lipid subjected to reversible and transient changes at its head-group, with phosphorylation 
on position 3,4 and/or 5. This produces seven distinct phosphoinositides species, involved in the 
regulation of different  cellular metabolic pathways [22]. PtdIns is not only the precursor of the 
phosphoinositides species, but it is also an important source of the glycosylphosphatidylinositol 
(GPtdIns), an anchor for the membrane-destined proteins. Itis synthetized on the cytosolic side of 
ER with subsequent flipping of the product inside the lumen, where the COOH terminus of the 
proteins can be covalently attached.  
PtdIns(3)P is abundant in the cytoplasmic leaflet of the membrane of early endosomes. It has also 
been detected on internal vesicles of multivesicular bodies. PtdIns(3)P is made primarily by 
phosphorylation of PtdIns by class III PtdIns3K (22), secondarily by class II PtdInsP3K. In 
addition, PtdIns(3)P can be generated by dephosphorylation of PtdIns(3,4)P2 by Inpp4. PtdIns(3)P 
is degraded by 3’-phosphatases of the myotubularin family [46] and mutations in members of this 
family cause myotubular myopathy and Charcot-Marie-Tooth syndrome type 4B [47]. PtdIns(3)P 
plays very important roles in membrane traffic, directing endosome progression and phagosome 
maturation and regulating autophagy, and the production of reactive oxygen species (ROS) [48, 
49].  
PtdIns(4)P is enriched in the Golgi apparatus and, at lower concentrations,  it is found on 
endosomes, plasma membrane, and ER. PtdIns(4)P is generated from PtdIns by two types of PtdIns 
4-kinase (PtdIns4K; not to be confused with PtdInsP4K). PtdIns(4)P can be degradated or 
converted to more complex inositide species. PtdIns(4)P is key to sphingolipid synthesis in the 
Golgi complex, where it interacts with various proteins that include [50]. 
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PtdIns(5)P is not very abundant so its distribution, metabolism and functions have not been fully 
characterized. PtdIns(5)P can be made from PtdIns(3,5)P2 by dephosphorylation operated by 
myotubularins, which are 3’-phosphatases [51]. It is used as a substrate by type II PtdInsP5K to 
generate PtdIns(4,5)P2 (302), but this pathway is likely a minor contributor to the overall 
biosynthesis of PtdIns(4,5)P2 (307). PtdIns(5)P may also play a role in traffic between the late 
endosome and the plasma membrane, where PtdIns(3,5)P2 and PtdIns(4,5)P2, respectively, are 
enriched.  
PtdIns(3,4)P2 can be produced from PtdIns(4)P by phosphorylation at the 3’ position of the inositol 
ring by the class II PtdInsP3K, from PtdIns(3)P by type II PtdInsP4K or from dephosphorylation 
of PtdIns(3,4,5)P3 by 5’ phosphatases (73). PtdIns(3,4)P2 can be converted in PtdIns(3)P and 
PtdIns(4)P by removal of the 4’ phosphate or 3’ phosphate, respectively, by specific phosphatases. 
PtdIns(3,4)P2 is a potent survival signal and it can positively regulate tumor cell invasion [52]. 
PtdIns(4,5)P2 constituted 1–2 mol% of the phospholipids [53] at the inner leaflet of the plasma 
membrane. It is produced from PtdIns(4)P and PtdIns(3)P by specific kinases or from 
PtdIns(3,4,5)P3 by dephosphorylation. Furthermore, PtdIns(4,5)P2 itself can be dephosphorylated 
by 5’-phosphatases [54]. PtdIns(4,5)P2 is substrate for lipases and kinases that generate several 
signaling molecules. For example, it can be phosphorylated by PtdInsP3K to produce 
PtdIns(3,4,5)P3, which is a critical mediator of cellular activation or it can be hydrolyzed into IP3, 
began  a Ca2 -mobilizing agent[55].  
It is produced by phosphorylation of PtdIns(3)P on position 5’ by PtdInsK-FYVE [56]. 
PtdIns(3,5)P2 is dephosphorylated on the 3’ position by myotubularins to generate PtdIns(5)P or, 
more commonly, it is dephosphorylated on the 5’ position by Sac3. Its physiological role is not 
total clear, but PtdIns(3,5)P2 seems to be implicated in the osmotic stress response, in autophagy, 
and in the control of ionic channel activity [57]. PtdIns(3,5)P2 is found on late endosomal [58]. 
PtdIns(3,4,5)P3 makes up 1% of the total lipid (349) and it is one of the major survival signal. 
PtdIns(3,4,5)P3 is generate from PtdIns(4,5)P2 by class I PtdInsP3-kinases. It can be 
dephosphorylated by both 3’phosphatases and 5’phosphatases to give PtdIns(4,5)P2 and 
PtdIns(3,4)P2, respectively. A number of important signaling proteins, such as PLC-, Akt, Vav, 
and PDK isoforms, bear PtdIns(3,4,5)P3-binding domains that recruit and/or activate them at the 
membrane.  
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Sphingolipids 
Sphingolipids (SLs) are minor cell components and they reside in the external layer of the plasma 
membrane with the hydrophilic headgroup protruding toward the extracellular environment [59].  
 
 
Figure 4. Common sphingolipids structure 
 
The basic building block of sphingolipids is sphingosine, (2S, 3R, 4E)-2-amino-4- octadecene-1,3-
diol (Fig. 4); the C1-phosphate ester of sphingosine is commonly named as sphingosine-1-
phosphate [60]. Ceramide, the simplest SL, consists of a sphingoid base to which a fatty acid is 
attached at C-2 via N-acylation; the additions of oligosaccharides to sphingosine giving rise 
glycosphingolipids (GSLs), as glucosylceramide (GlcCer) and galactosylceramide (GalCer); the 
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subsequent addition of a sulfate group to a galactosylceramide produces sulfatide, an anionic 
sulfoglycolipid. By adding a phosphorylcholine moiety, it results sphingomyelin (SM), a very 
abundant membrane lipid. Glycosphingolipids with a capping N-acetylneuraminic acid are known 
as gangliosides [61]. 
 
 
Figure 5. Subcellular compartmentalization of sphingolipid metabolism. Adapted from Grassi et al, 
2019 [62]. 
 
Sphingolipid Metabolism 
Sphingolipids (SLs) are a class of natural lipids comprised of sphingosine; the predominant 
mammalian sphingoid bases contain 18 carbon atoms [63]. The de novo biosynthesis of SLs starts 
at the cytosolic leaflet of membranes of the endoplasmic reticulum (ER), with the condensation of 
serine and palmitoyl CoA by serine palmitoyl transferase [64] to form 3-ketosphinganine, which is 
subsequently reduced by 3-ketosphinganine reductase to produce sphinganine. Dihydroceramide 
synthase (CerS) [65] next acylates sphinganine to form dihydroceramide. In humans this is 
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achieved by six distinct CerS genes (known as LASS genes) that encode for a family of CerS 
enzymes with differing selectivity for the CoA-activated fatty acid [65]. The majority of 
dihydroceramide is transformed into ceramide (Cer) by dihydroceramide desaturase/reductase 
(DES1), which inserts a trans 4 – 5 double bond [66]; ceramide is the central molecule in the 
sphingolipid biology. Ceramide is also generated during the catabolism of SLs that occurs in 
lysosomes, and rapidly converted to sphingosine which is largely recycled. Ceramide synthase is 
able to use as substrate both sphingosine and sphinganine with similar efficiency [67] so  ceramide 
can be also formed by N-acylation of sphingosine produced by the catabolism of complex 
sphingolipids.  
The neo-synthesized ceramide could reach directly the membrane or be transported to the Golgi 
complex, where it serves as a substrate for production of complex sphingolipids (Fig. 5). Ceramide 
is the precursor of at least five different products: 
(1) Ceramide can be glycosylated to galactosylceramide (GalCer) at the lumenal leaflet of the 
ER by the transfer of galactose from a UDP-galactose donor [68]. GalCer can be diversified into 
Sulfatide or GM4 by sulfation or glycosylation at its 3-O-position with Neu5Ac [69].  
(2) Ceramide can be phosphorylated by ceramide kinase to generate ceramide-1-phosphate. The 
subcellular localization of this enzyme is not clear but has been suggested to be the PM  [70], Golgi 
apparatus [71], and the cytoplasm [72] .  
(3) Ceramide can be deacylated to sphingosine and free fatty acid by various forms of 
ceramidases, acting at either neutral (PM [73]), alkaline (ER/Golgi complex [74]), or acidic 
(lysosomal [75]) pH. Ceramidase activity has also been reported in mitochondria [21].  
(4) Ceramide can be converted to SM. The synthesis of SM from ceramide occurs at the lumenal 
leaflet of the Golgi apparatus by transfer of phosphorylcholine from phosphatidylcholine (PC) to 
ceramide, with diacylglycerol formed as a by-product [76, 77]. Two SM synthases have been 
identified: SMS1 is located at the Golgi apparatus and SMS2 at the PM [78, 79]. Since ceramide 
is synthesized in the ER, there are two mechanisms for transferring ceramide to the Golgi apparatus 
for its metabolism to SM: vesicular and non-vesicular transport mechanisms. With the non-
vesicular transport, ceramide is transported to the cytosolic leaflet of the trans-Golgi membrane by 
the ceramide transfer protein (CERT), in an ATP-dependent manner [80].  CERT transfers 
ceramides of relatively short acyl chain length (C16 – 20) from the ER specifically for SM synthesis 
in the Golgi apparatus [81]. 
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(5) With the vesicular transport, ceramide is transported to the cytosolic leaflet of the cis-Golgi 
membrane; here, ceramide can be glycosylated to glucosylceramide (GlcCer), by glucosylceramide 
synthase (GCS). [82]. 
 
In alternative pathway, ceramide is phosphorylated in ceramide-1-phosphate at the plasma 
membrane by ceramide kinase (CERK). Ceramide-1-phosphate can be hydrolyzed by lipid 
phosphate phosphatase (LPP) to give ceramide [83]. Acid, alkaline and neutral ceramidases are 
capable of deacylating ceramide to generate pools of sphingosine at specific cellular locations. This 
sphingosine can be both phosphorylated to sphingosine-1-phosphate (S1P) by sphingosine kinase 
1 (SK1), which operates at the plasma membrane and in the extracellular matrix, or by sphingosine 
kinase 2 (SK2) which is located at the ER, nucleus and mitochondria [62]. S1P levels can be 
downregulated by S1P phosphatase. The cellular orchestration of these complex interconversions 
between SLs is called the sphingomyelin cycle, and is an evidence to the role of these SLs in extra- 
and intracellular signaling pathways. The only currently known exit pathway from this 
interconnected SL metabolism is the degradation of S1P by S1P-lyase at the ER [61].  
In the cytosolic side of the cis-Golgi apparatus membrane, GCS catalyzes the glycosylation of the 
primary hydroxy group in ceramide, using UDP-glucose as a donor glycoside, to generate GlcCer. 
GlcCer can either directly reach the plasma membrane, transported in a non-vesicular manner 
(GLTP transport protein) [84, 85] or be translocated to the luminal side of the Golgi either with 
FAPP2 or vesicular transport [86, 87]; here GlcCer flips into the Golgi lumen and then it is 
glycosylated by galactosyltransferase (GalT1) to give lactosylceramide (LacCer). 
Lactosylceramide, that, once produced, stays at luminal side of Golgi. [88]. Lactosylceramide is 
extended sequentially at either the 3-O-positon or the 4-O position; most of these GSLs consist of 
alternating and branched combinations of a- or b- linked glucose, galactose, N-galactosamine and 
N-acetylglucosamine. Of particular interest are the gangliosides, that is, lactosylceramide-derived 
sphingolipids containing capping N-acetylneuraminic acid (sialic acid) units. In 1962 
Svennerholm, a pioneer in ganglioside research, suggested a nomenclature of brain gangliosides 
[89]. In this nomenclature G stands for ganglioside, A for asialo-, M for monosialo-, D for disialo-
, and T for trisialoganglioside [90, 91]. Specific sialyl transferases convert lactosylceramide 
stepwise into GM3, GD3, and GT3. Lactosylceramide and each of its sialylated derivatives serve 
as precursors for complex gangliosides of the 0, a, b, and c series. These different series are 
characterized by the presence of no (0 series), one (a series), two (b series), or three sialic acid 
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residues (c series) linked to the 3-position of the inner galactose moiety. Gangliosides from the 0 
and c series are only found in trace amounts in adult human tissues.  
 
 
 
Figure 6. Schematic biosynthetic pathway of glycosphingolipids. Adapted from Olsen et al, 2017 [92]. 
 
Biological functions of sphingolipids 
In recent years, there is more and more evidence that SLs are not merely structural components of 
biological membranes, but are also regulators of cellular events.  
The simple SLs, ceramide, ceramide-1-phosphate, sphingosine, and S1P are involved in several 
cellular events such as proliferation, differentiation, motility, growth, senescence, and apoptosis.  
Furthermore, complex SLs are involved in cell physiology by acting as antigens, as mediators of 
cell adhesion, binding agents for microbial toxins and growth factors, and as modulators of signal 
transduction [66].  Within the simple SLs, Cer and S1P are the best investigated components; they 
 20 
have an opposite role in apoptosis processes and the levels of these two molecules regulates the 
balance between cell survival and death.  
It has been known for years that ceramide has a role in apoptosis. The ceramide levels are increased 
by several extracellular signals, inducing apoptosis: heat shock, ionizing radiation, oxidative stress, 
progesterone, vitamin D3, tumor necrosis factor (TNF)-a, interleukin (IL)-1a, IL-1b, interferon-g, 
Fas ligand, oxidized low-density lipoprotein (LDL) and nitric oxide [93]. 
At today, the mechanisms supposed through which ceramide induces apoptosis are two [94]. In the 
first mechanism, ceramide produced in the plasma membrane acts as a second messenger and it 
binds to proteins whose activity it regulates; these proteins are the ceramide-activated protein 
phosphatase, protein kinase Cz , kinase suppressor of Ras, phospholipase A2, cathepsin D, Jun-N-
terminal kinases (JNKs), Ras and Rac, and Src-like tyrosine kinases [66]. In the second mechanism 
acts a signaling lipid: it can self-associate in the plasma membrane [95] and stimulate the fusion of 
GSL- and cholesterol-containing rafts into large signaling macrodomains (signaling platforms) 
[96]. In an additional mechanism, ceramide might induce apoptosis interacting with mitochondria. 
With a still unknown vehicle, ceramide is transported to mitochondria from ER and here forms 
membrane channels through which cytochrome c and small proteins are transported, leading to 
activation of the caspase-dependent apoptotic pathway [97, 98]. 
Likewise, S1P can act as both a first and second messenger but with opposite roles respect 
ceramide. As a first messenger, S1P regulates processes such as cytoskeletal rearrangement, cell 
migration, angiogenesis and immunity and lymphocyte trafficking. As an intracellular second 
messenger, S1P mediates calcium homeostasis, cell growth, tumorogenesis and suppression of 
apoptosis [66]. S1P can trigger signal transduction pathways by acting on the same cell from which 
it is secreted, by acting in an autocrine manner [96].  
S1P seems to have opposite effects to ceramide in the pathways relating to cell growth and survival. 
Ceramide is implicated in growth-inhibitory and pro-apoptotic effects, contrariwise S1P is 
implicated in cell growth and inhibition of ceramide-mediated apoptosis. Moreover, sphingosine 
appears to act in a similar fashion to ceramide, whereas ceramide-1- phosphate shares similar 
functions with S1P [103]. This suggests that the balance between survival and death may depend 
on a delicate equilibrium between intracellular levels of each of these SLs. 
Sphingomyelin is involved in plasma membrane signal transduction, cholesterol efflux and intra- 
cellular lipid and protein trafficking [99, 100]. As mentioned above, the major cellular site of SM 
synthesis is the Golgi apparatus [76, 77], but SM have also been observed in nuclear membranes 
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and in mitochondria. In these membranes, SM are believed to be an important source of ceramides 
for the nuclear [101] and mitochondrial [102] apoptotic cascades, respectively.  
Gangliosides are ubiquitously found in tissues and body fluids and are more abundantly expressed 
in the nervous system [103]. In cells, gangliosides are primarily, but not exclusively, localized in 
the outer leaflets of plasma membranes and here are involved in cell-cell recognition and adhesion 
and signal transduction. In addition to cell plasma membranes, gangliosides have been shown to 
be present on nuclear membranes where play important roles in modulating intracellular and 
intranuclear calcium homeostasis and the ensuing cellular functions [104].  
 
(Glyco)sphingolipids in membrane domains 
Contrariwise of phosphoglycerolipids, SLs and GSLs are not distribute homogeneously in the outer 
plasma membrane. They form small (10–200 nm), heterogeneous, highly dynamic (ca. 0.1–
1000ms), sterol- and sphingolipid-enriched domains, called “lipid rafts”, that compartmentalize 
cellular processes on the surface of plasma membrane [105, 106]; in these semiordered lipid 
microdomains, SLs are involved in cell adhesion/recognition processes and signal transduction 
pathway. These microdomains exist in a gel-like liquid-ordered phase (lo), which has a lower 
diffusion rate than the surrounding liquid-disordered (ld) phosphoglycerolipid-rich plasma 
membrane [61]. Initially, proof of the existence of lipid microdomains was their isolation by 
extraction of membranes at 4°C in the presence of specific detergents: the so-called detergent 
resistant membrane domains (DRMDs). The presence of lipid rafts in vivo is supported by several 
lines of evidence, including the results of electron microscopy using the freeze-fracture technique 
[107], a single-particle tracking study  [105], a fluorescence resonance energy transfer study [108] 
and a chemical crosslinking study [109].  Rafts have been shown to exist in both the extracellular, 
as well as the cytosolic, layer of the plasma membrane [110]. The connection between both layers 
is not clear, but the crossing of long- and very-long-chain fatty acyl chains of sphingolipids through 
both layers, interacting with saturated acyl chains on phospholipids, appears likely to contribute to 
the involvement of both lipid layers [99]. 
In lipid rafts, glycosphingolipids are usually highly asymmetrically enriched in the external leaflet 
of the plasma membranes, with the oligosaccharide chain protruded toward the extracellular space, 
where the sugar residues can engage cis and trans interactions with a wide variety of cell surface 
and extracellular molecules [111]. In fact, several proteins, including GPI-anchored proteins, 
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flotillins, caveolins, G-protein- coupled receptors, and certain receptor tyrosine kinases such as the 
epidermal growth factor receptor and the insulin receptor, appear to associate with these 
microdomains. Principally, two hypotheses have been developed to explain how lipid rafts 
accumulate and remain in the membrane as an entity. One hypothesis proposes that the headgroups 
of sphingolipids interact with each others amide and hydroxy/carboxy group, therefore holding 
sphingolipids together [112], while cholesterol fills the space between the bulky sphingolipid 
headgroups and is additionally kept in place by hydrogen bonds and van der Waals interactions 
between its 3-OH group and the sphingolipid amide groups [113]. The second hypothesis attributes 
the tight assembly in rafts to the interaction of mainly saturated acyl chains, which also favours 
cholesterol packing [114]. A major subclass of rafts are caveolae which are invaginations of the 
cell membrane characterized by the abundance of caveolin, a palmitoylated membrane protein that 
causes rafts to polymerize [115]. Most of the functions of caveolins are currently unclear, but they 
have been proposed to act as cholesterol sensors and thereby regulate the number of lipid rafts in 
the cell membrane [116]. 
Lipid membrane domains are characterized not only by a peculiar lipid composition, but also by 
the presence of specific subsets of membrane proteins. For the cell biology of neurons, the most 
relevant examples of proteins whose functions are modulated by the association with lipid 
membrane domains are represented by membrane receptors. Some of these receptors are already 
resident in lipid domains at the resting state, and, upon activation, they can propagate signals to 
other components intrinsically present in the lipid membrane domain; in other cases, activation of 
a signaling protein involves its translocation from/to lipid rafts to/from a non-raft membrane region 
or other intracellular sites [117]. As an example, the lipid raft-dependent lateral interaction 
involving GM1 ganglioside (and likely other ganglio-series structures, highly expressed in 
neurons) and the Trk family neurotrophin receptors. Association with ganglioside-enriched 
membrane domains is important for the cross-talk of Trk receptors with Src family non-receptor 
tyrosine kinases, which are typically highly enriched in neuronal lipid rafts [118, 119] in a cell- 
and stage-specific manner, and whose activity is as well regulated by gangliosides. The main roles 
of lipid membrane domains as signaling platforms involved in events crucial for neuronal survival, 
synaptic transmission, axon growth, guidance, and regeneration are summarized in Fig. 7.  
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Figure 7. The multifaceted roles of lipid membrane domains in the nervous system. Adapted from 
Aureli et al, 2015 [117]. 
 
Myelin development, damage and repair 
The rapid transduction of electrical impulses is required for the efficient function of the vertebrate 
nervous system. The conduction velocity of these impulses is increased by the presence of myelin, 
an insulating layer surrounding the axon [120, 121].  In the CNS, the oligodendrocyte is the resident 
cell type responsible for the production of myelin that consists of oligodendroglial plasma 
membrane loops strongly wound concentrically around the axon. Mature myelin consists of up to 
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160 membrane layers, and internodes extend up to 1.7 mm in the CNS and up to 2 mm in the PNS 
[122, 123]. In postnatal development, the myelin membranes of an oligodendrocyte may grow by 
as much as 5,000 μm2 per day [124].  
The CNS myelinating oligodendrocytes are terminally differentiated cells with a limited ability to 
respond to damage. They depend from the availability of their precursors, the oligodendrocyte 
progenitor cells (OPCs) that can proliferate, migrate and differentiate into defined progeny [125], 
either oligodendrocytes or astrocytes depending on the context [126, 127].  Generation of OPCs in 
the spinal cord occurs in two steps. The first is ventral, with OPCs observed initially within the 
ventricular zone of the motor neuron progenitor (pMN) domain of neuroepithelium, in early 
embryonic life [128, 129]. Subsequently, the second step occurs in the dorsal spinal cord and 
hindbrain/telencephalon of the brain in late embryonic development and early post-natal life [130-
132]. These proliferating cells migrate into the developing white matter, exit the cell cycle, undergo 
differentiation into mature oligodendrocytes, and begin to express a subset of myelin-associated 
proteins and other specific markers, several of which are glycosphingolipids [133] (Fig. 8). 
 
Figure 8. Schematic representation of the morphological and antigenic characteristics of cells 
of the oligodendroglial lineage differentiating from mitogenic progenitor cells to mature 
myelinating OLGs. Multi-potent neural stem cells (nestin+) are specified into oligodendrocyte progenitor 
cells (OPCs; A2B5+, PDGF R+, and NG2+) by exposure to sonic hedgehog (SHH) and fibroblast growth 
factor (FGF), whereas bone morphogenic proteins (BMPs) inhibit this specification. This specification 
involves the transcription factors Olig2, Nkx2.2, Mash1, MyT1, Nkx2.6, Gli2, and Sox 8/9/10. OPCs can 
differentiate into multiple cell types including astrocytes, neurons, and Schwann cells. Differentiation along 
the oligodendroglial lineage to pre-oligodendrocytes/immature oligodendrocytes (O4+/ GalC+) is 
potentiated by the growth factor IGF-1, the cytokine CNTF, and the thyroid hormone T3, and requires the 
transcription factors Olig1/2, Sox10, and Nkx2.2/2.6. Conversely, BMPs and transcription factors Sox5/6 
prevent this differentiation. Differentiation into mature oligodendrocytes is associated with acquisition of 
myelin-related proteins, MBP, MAG, MOG, oligodendrocyte–myelin glycoprotein (OMgp), and 2 ,3 -cyclic 
nucleotide 3 - phosphodiesterase (CNPase).  Adapted from Miron et al, 2011 [134]. 
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Upon first contact with an axonal membrane, the extremity of the OPC membrane is either retracted 
or stabilized (Fig. 9); when it is stabilized, a specialized membrane domain for continued axoglial 
communication is created. This initial contact stimulate a number of molecular rearrangements in 
the future myelinating cell, including the association of the tyrosine-kinase fyn with lipid-rich 
membrane microdomains [135], the suppression of RhoA activity [136], the local enrichment of 
phosphoinositides in the glial membrane, as PIP2 and PIP3  [137-139], the localization and activity 
of polarity proteins change [140, 141] and reorganization of cytoskeletal.  
Myelin lipids have a high lateral mobility and the cholesterol content is likely to limit the 
membrane’s fluidity, thereby affecting its intracellular trafficking and myelin 
compartmentalization. The compaction of multiple membrane layers progresses from the abaxonal 
layers toward the inner tongue with a delay of two to three wraps behind the leading edge [139], 
allowing the growing sheath to expand underneath the previous layer. This compaction requires 
specialized adhesive proteins and the removal of molecules that prevent compaction. Initially, the 
intracellular surface of the glial membrane is inhibitory to tight appositions owing to highly charged 
phospholipids, such as PIP2. However, negatively charged membrane surfaces attract basic 
proteins MBP [142]. MBP is abundant (8% by mass) and shows a high affinity to PIP2 [143]. By 
neutralizing membrane phospholipids, MBP pulls together two bilayers similar to a zipper [144], 
forming a the major dense line that allows myelin to grow [145]. Oligodendrocytes that lack MBP 
fail to form compact myelin, while peripheral myelination can occur without the incorporation of 
MBP because seems to be compensated for by the basic intracellular domain of P0 [146] and by 
protein 2 (P2/Pmp2) [147].  
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Figure 9. Schematic model of the differentiation of a committed oligodendrocyte progenitor cell 
(OPC) into a mature myelinating oligodendrocyte. Adapted from Nave et al, 2014 [148].  
 
Lipids in myelin   
Myelin is a concentrically laminated membrane structure surrounding an axon around [149]. The 
myelin lamella is formed by fusion of the apposed inner leaflets of the plasma membrane in glial 
cells, with no intervening cytoplasm. Myelin provides the structural basis for saltatory action 
potential propagation, which accelerates nerve conduction 20–100-fold compared with 
nonmyelinated axons of the same diameter [148]. 
The myelin membrane originates from and is a part of the oligodendroglial cells in the central 
nervous system (CNS: brain and spinal cord) and the Schwann cells in the peripheral nervous 
system (PNS: nerves). In the CNS one oligodendrocyte makes myelinate multiple segments on 
many axons, while in the PNS one Schwann cell forms a single myelin sheath. Although some 
molecular or morphological differences, the basic sheath arrangement, characteristics and function 
between peripheral and central myelin is essentially the same. 
A myelinated axon is interrupted by non-myelinated regions, called nodes of Ranvier, and can be 
divided in four distinct domains, node (N), paranode (PN), juxtaparanode (JXP) and internode 
(INT) (Fig. 10).  At the nodes of Ranvier, Neurofascin 186 (Nf-186) supports the clustering of Na+ 
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channels, that regulate electrical impulse conduction. The nodal Na+ channels are separated from 
the juxtaparanodal K+ channels via the paranode, where Neurofascin 155 (Nf-155) binds tightly to 
the axonal complex of Contactin and Contactin-associated protein (Caspr). At the juxtaparanode, 
clustered K+channels are associated to Caspr-2 and Contactin-2.  
 
 
 
 
Figure 10. Schematic of node of Ranvier organization. Adapted from Podbielska et al, 2013 [150]. 
 
One of the biochemical characteristics distinguishing myelin from other biological membranes is 
its high lipid-to-protein ratio, where lipids representing 80% of its dry weight [151]. The lipids are 
assembled with myelin-specific membrane proteins: myelin proteolipid protein PLP), an intrinsic 
(integral) membrane protein, myelin basic protein (MBP) an extrinsic (peripheral) membrane 
protein, myelin-associated glycoprotein (MAG), myelin oligodendrocyte glycoprotein (MOG), and 
2′3′-cyclic-nucleotide 3′-phosphodiesterase (CNP).  
 
The three main classes of lipids comprising CNS myelin are cholesterol, sphingolipids and 
phospholipids with a constant molar proportion of 2:1:2 [152].  
 
 
Table 1. Comparison of the human and rat brain composition. Protein and lipid values are given in 
percentage of the dry weight; everything else in total lipid weight percentage. Adapted from Quales et al, 
2002 [153]. 
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The myelin membrane contains a high level of two galactosphingolipids, galactosylceramide 
(GalCer) and 3-O-sulfogalactosylceramide (sulfatide), account for about 20 and 5 % of myelin 
lipids respectively [154]. How described in the above sections, the synthesis of these 
galactosphingolipids involves two sequential steps (Fig. 11), the addition of galactose from UDP-
galactose (UDP-Gal) to ceramide, catalyzed by the UDP-galactose:ceramide galac- 
tosyltransferase (CGT) and the subsequent addition of the sulfate group by the enzyme 3’-
phosphoadenosine-5’-phosphosulfate:cerebroside sulfotransferase (CST) [155]. 
Galactosylceramides and sulfatides with long chain fatty acid moieties, in particular 24:0 and 24:1 
fatty acids, are the most typical myelin lipids [156].  
 
 
 
Figure 11. Structure and biosynthetic pathway of sulfatide, the major sulfoglycolipid in the 
nervous system. 3-O-sulfogalactosylceramide is highly heterogeneous in its fatty acid composition. 
The main fatty acids found in mature CNS myelin are long chain fatty acids (24:0 and 24:1), including 
a significant amount of 2-hydroxylated fatty acids. Sulfatide synthesis requires the addition of 
galactose from UDP-galactose (UDP-Gal) to ceramide, catalyzed by the UDP-galactose:ceramide 
galactosyltransferase (CGT, EC 2.4.1.45, encoded by the ugt8 gene), and the subsequent addition of 
the sulfate group by the enzyme 3’-phosphoadenosine-5’-phosphosulfate:cerebroside sulfotransferase 
(CST, EC 2.8.2.11, encoded by the gal3st1 gene). 
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The essential role of sphingolipids, in particular GalCer and sulfatide, in myelin structure has 
been studied using animal models lacking the enzymes responsible for their synthesis.  
CerS2 null mice have greatly reduced levels of sphingolipids with very long chain fatty acyl 
chains (C22:0-C24:0) and a massive decrease in galactosylceramides and sulfatides in myelin 
[157]. Nevertheless, CerS2 null mice form relatively normal myelin with mild structural 
defects, such as focal detachments of individual or groups of myelin lamellae.  
CGT knock-out mice, that completely lack GalCer or sulfatide, able to form myelin with an 
apparently normal structure with normal major dense and intraperiod line periodicity [158]; this 
could be due to a partial compensation of the loss of these galactolipids by synthesizing 2-
hydroxylated GlcCer, usually not present in myelin. Despite the presence of compact myelin, 
these animals exhibit tremor, splaying of the hind limbs and ataxic locomotion that worsens 
progressively, resulting in death of most animals by the third month of age [159]. In fact, they 
present disruption of nerve conduction with an action potential decrease respect a wild type 
mice [159] and, a more detailed analysis of the structure of their myelin revealed ultrastructural 
abnormalities; the CNS myelin sheaths are thinner, nodal length is increased, lateral loops are 
widely spaced, the tight junctions are destroyed, suggesting that the formation of these junctions 
may be dependent on the presence of this lipid. In addition, CGT (-/-) mice exhibit a significant 
increase in cellularity in the spinal cord [160, 161] and a decrease of proliferation and survival 
rate of oligodendrocyte precursors. In the other hand, the PNS myelin in the knock-out mice 
appears normal suggesting that galactolipids might be less critical in the formation and 
maintenance of PNS myelin sheath structure [158].   
CST (-/-) mice cannot synthesize sulfatide, while the levels of GalCer, other glycolipids, and 
phospholipids are not significantly altered [162]. These mice produce compact myelin, even if 
it is thinner than that of normal mice and shows alterations in the paranodal structure similar to 
those of CGT knock-out mice. The phenotype of these mice is similar but milder than that of 
CGT (-/-) mice in terms of age of onset, life span and severity of symptoms and they survive 
for more than 1 year [163].  CST-deficient mice are born healthy but start displaying hind limb 
weakness around 6 weeks of age, followed by pronounced tremor and progressive ataxia. 
Electron microscopy analysis of myelinated nerve fibers of these mice, revealed disorganized 
termination of the lateral loops at the node of Ranvier and deteriorated clusterization of Na+ 
and K+  channels [164]. These ion channels alterations are present both in CNS and in PNS in 
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mutant mice and are accompanied by an altered distribution of proteins involved in the structure 
of nodes, such as Caspr, contactin and neurofascin155 (NF155) [164]. In addition, in these 
animals is observed an increased number of oligodendrocytes and oligodendrocytes mature 
earlier and in greater number [165, 166]. This increase is determined by an increased 
proliferation and by a reduced rate of apoptotic death in the oligodendrocytic lineage cells 
[166].  
1-month-old CGT mutant mice form abundant myelin but it is characterized by structural 
features associated with sheath immaturity such as uncompacted and redundant myelin profiles 
[158, 159, 167]. In contrast, the same age CST mutant mice showed no difference in the 
frequency of redundant myelin and revealed only a modest increase in the frequency of 
uncompacted myelin, suggesting that myelin development is relatively normal. The difference 
between the CGT and CST mutants indicates that GalCer is critical for myelin development 
while sulfatide is less essential at early stages of maturation [168]. Sulfatide, therefore, seems 
to play a role in maintaining the integrity of the major dense line, either directly or indirectly 
by helping to organize the plasma membrane components responsible for intra-myelin stability 
and adhesion [169].  
The structure-specific roles seem to be linked to the ability of GalCer and sulfatide to form and 
to stabilize specific lateral domains in the membrane of myelin forming-cells and in the myelin 
sheath [154]. In particular, GalCer- and sulfatide-rich domains in the oligodendrocyte 
membranes regulate the correct sorting, trafficking, co-clustering and lateral distribution of the 
major myelin proteins [170]. While in the early stages of myelin formation galactolipid levels 
are absent or very low and only a few of the typical myelin proteins are associated with lipid 
rafts, during the mid-myelination stage, GalCer and sulfatide are synthesized at detectable 
levels and the PLP and MOG proteins tend to localize in lipid rafts; later, in the final stages of 
myelination, myelin- MAG and MBP are also translocated into lipid rafts [171-173]. Recent 
studies have demonstrated a differential involvement of GalCer-rich and sulfatide-rich 
membrane domains in modulating the function of this specific myelin proteins, in particular has 
been analyzed the effect of myelin galactolipids on the lateral organization and membrane 
dynamics of two myelin proteins, PLP and MBP [171].  
The differential involvement of GalCer-rich and sulfatide-rich membrane domains in 
modulating the function of this specific myelin proteins has been studied by separately 
overexpressing CGT or CST on a galactolipid-null background, using the rat immature 
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oligodendrocyte cell line OLN-93, that does not produce galactolipids [154]. This study 
revealed that membrane association and dynamics (as lateral motility mobility in intact cells) 
of MBP is ordered by GalCer, while those of PLP are regulated by sulfatide (Fig. 12). This 
clearly indicates the importance of the formation of distinct lipid membrane domains in the 
myelin membrane for the lateral organization of specific myelin proteins as MBP and PLP.  
 
 
 
Figure 12. Association with specific sulfatide-rich domains regulates the function of PLP. The 
membrane association and dynamics of PLP are sulfatide-dependent while those of MBP are GalCer-
dependent. Adapted from Grassi et al, 2015 [154].  
 
Additionally, GalCer and sulfatide present in the apposed extracellular surfaces of the myelin 
sheath can do trans-interactions and form specialized “glycosynapse”, which stabilized the 
myelin wrapping [174, 175]. Moreover, for long-term axon-myelin stability is required another 
oligosaccharide mediated trans interactions between the gangliosides GD1a and GT1b, in 
specialized domains of the axonal surface, and MAG [176], whose correct localization in the 
myelin membrane, is in turn regulated by the association with galactolipid rich domains [173] 
(Fig. 13).  
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Figure 13. Glycolipid-enriched membrane domains in myelin. Glycolipid–glycolipid and 
glycolipid–protein interactions play multiple roles in myelin formation, maintenance and functioning 
but also in axon-myelin stability and communication. GalCer and sulfatide on opposing surfaces of 
the myelin wrap interact with each other through trans carbohydrate–carbohydrate interactions 
forming a “glycosynapse” causing transmembrane signaling which results in clustering of membrane 
domains and loss of cytoskeleton integrity, leading to compaction and formation of mature myelin. 
On the other hand, GD1a and GT1b gangliosides, enriched in axonal lipid rafts, interact with MAG 
resulting in transmembrane signaling. MAG can also interact with Nogo-R1 (NgR1) which in turn 
interacts with signaling molecules p75/TROY and LINGO-1, leading to RhoA activation and axon 
outgrowth inhibition. Lateral interaction of GD1a and GT1b with p75 is important for the 
organization of NgR1 complex. Adapted from Aureli et al, 2015 [117]. 
 
The available information indicate that GalCer is primarily involved in myelin formation and 
maturation, while sulfatide contributes to the long term stability of myelin structure, in 
particularly affecting the integrity of the nodal and paranodal regions [145].  
In addition to cerebroside, the other major myelin lipids are cholesterol, phosphatidylcholine, 
phosphatidylethanolamine, much of the latter are plasmalogens and there is less sphingomyelin. 
Minor glycosphingolipid components (0.1% to 0.3%) include gangliosides, especially GM1 
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and GM4 [177]. The role of plasmalogens in membranes has not been elucidated, but they seem 
to play a role in membrane fusion processes and membrane dynamics. In fact, in knockout 
mouse for Dhapat, a peroxisomal enzyme essential for plasmalogen synthesis, reduced CNS 
myelination is observed together with abnormal paranodal structure and reduced corpus 
callosum conduction velocity [151].  
 
Demyelination Process in Multiple Sclerosis 
The term “demyelination” indicates a loss of myelin with a consequent axonal damage, 
determining impairment of the conduction of signals. According to pathogenesis, 
demyelinating diseases of the CNS can be classified into several categories: demyelination due 
to inflammatory processes, viral demyelination, demyelination caused by acquired metabolic 
derangements, hypoxic–ischaemic forms of demyelination and demyelination caused by focal 
compression [178].  MS is the most common human demyelinating disease it is thought to be 
caused by the interaction of multiple genetic and environmental factors. The exact cause of 
multiple sclerosis still remains elusive, but it established that Multiple sclerosis is an immune-
mediated disease in which the body's immune system attacks the CNS. In the most widely 
accepted hypothesis concerning MS pathogenesis, CD4+ Th1 cells release cytokines and 
mediators of inflammation that may cause tissue damage, CD4+ Th2 cells may be involved in 
modulation of these effects and, as recent evidence suggests, Th17 cells, CD8+ effector T cells 
and CD4+, CD25+ regulatory T cells play a prominent role in MS immunopathology [179].  
Data collected from experimental autoimmune encephalomyelitis (EAE) studies suggest the he 
following immunopathological events: (1) initial T cell priming, (2) activation phase in the 
periphery, (3) migration of the pro-inflammatory T cells and monocytes across the blood-brain 
barrier (BBB), (4) amplification of local inflammation and activation of resident antigen 
presenting cells (APCs), such as microglia, (5) invasion of CNS parenchyma, resulting in 
damaging of oligodendrocytes, myelin sheath and axons [150, 179, 180]. The T cell priming 
occurs within systemic immune sites and it started by myelin antigens sensitization, among 
which myelin lipids. There are two different mechanisms for lipid antigen uptake, depending 
on antigen origin and its structure: lipids containing longer alkyl chains are transported to late 
endosomes, where CD1b molecules, specialized for binding long chain lipids, are located [181-
183]; lipids constituted by with alkyl chains whit multiple unsaturation sites or shorter saturated 
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tails are directed to early or recycling endosomes, where CD1c and CD1a molecules are located 
[184, 185]. Activated APCs, within secondary lymphoid organs, induce the activation and 
expansion of myelin-specific T cells, that consequently circulate searching for their specific 
antigens to become re-activated [186]. Upon acrossing the BBB, via interactions between 
adhesion molecules found on the surface of lymphocytes and endothelial cells [70], the 
autoreactive CD4+ T cells initiate the local pro-inflammatory cascade. In addition, a variety of 
effector mechanisms are induced: antibody-mediated cytotoxicity, oxygen and nitrogen 
radicals, pro-inflammatory cytokines and apoptosis-mediating molecules that damage 
oligodendrocytes, myelin sheaths and axons. The results of the local inflammation are the 
characteristic demyelinated plaques and astrocytic activation (gliosis), the are the major 
pathological hallmarks of the disease [187]. 
In MS, the demyelination is associated with disorganization of paranodal and juxtaparanodal 
domains: the paranodal and juxtaparanodal proteins become diffusely distributed along 
denuded axons and the aggregates disappear [188, 189]. Early alterations include the 
overlapping of Neurofascin (Nf)-155-positive paranodal structures with juxtanodal Kv1.2 
channels adjacent to actively demyelinating white matter lesions associated with injured axons 
[190]. Consequently, nodal sodium channels are then directly adjacent to juxtaparanodal 
potassium channels, leading to impaired saltatory conduction of action potentials (Fig 14). 
These data suggest that paranodal junctions might be the initial site of demyelination [150]. 
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Figure 14. Characteristics of the demyelination process. Demyelination destroys the paranode and 
sodium channels migrate laterally. Following this is sodium channels (Nav) redistribution and re-
expression of the immature isoform of sodium channels, Nav1.2. Persisting currents may cause 
conduction block and calcium overload, leading to axon injury and eventually loss. Adapted from 
Podbielska et al, 2013 [150]. 
 
Recent reports have suggested that some of the myelin-specific lipids may be key contributors 
to the pathogenic mechanism of MS. Individuals with MS disease are reported to have different 
myelin lipid compositions and elevated levels of anti-sulfatide Ab in biological fluids compared 
with healthy individuals [191]. Additionally, recent reports suggest that sulfatide might be a 
target autoantigen and abnormally released sulfatide from disrupted myelin could act as a glial 
activator [189]. Despite this insight into pathophysiology, the cause of MS remains unclear and 
definitive treatment of this frequent and chronic disease still obscure.  
 
Therapeutic approaches and remyelination promotion  
Remyelination, the phenomenon by which new myelin sheaths are generated around axons, is 
a common repair mechanism following an insult to the nervous system. The development of 
therapies aimed to promote remyelination in conditions in which axons are demyelinated, such 
as in multiple sclerosis, is an important therapeutic goal. Theoretically, remyelination is 
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beneficial in people with MS for its potential to restore myelin structure, recover neuronal 
conduction deficits and it could help to protect denuded axons from degeneration. 
Myelination begins with OPCs differentiating into oligodendrocytes, followed by their 
maturation into myelinating oligodendrocytes [192]. In developing zebrafish, myelination is 
rapid and oligodendrocytes produce myelin only during a short hour window, after this time, 
no new myelin sheaths are made by these oligodendrocytes. Likewise, in toxin-mediated 
demyelination rodent models, only newly differentiated oligodendrocytes formed from OPCs 
are able to remyelination and pre-existing mature oligodendrocytes do not remyelinate [193, 
194].  
In higher vertebrates, it is not still clear at what point after differentiation oligodendrocytes can 
no longer product new myelin sheaths. If also in these organisms, the oligodendrocytes have 
myelinogenic potential for only a few hours, there is a very brief window of opportunity for 
remyelination; consequently, remyelination mechanism probably requires ongoing 
oligodendrocyte differentiation. In this scenario, events that slow remyelination or 
oligodendrocyte differentiation, such as inflammation, could block the myelin repair, because 
oligodendrocytes become unable to myelinate axons.  
While in murine models, remyelination is rapid, extensive and associated with functional 
recovery [195], in MS patients this mechanism is highly variable: extensive in some cases, 
absent in others [196-198].  In MS subjects, the presence of extrinsic inhibitors in lesions, 
insufficient pro-regenerative factors and an impaired intrinsic capacity in oligodendrocyte 
lineage cells could be some of the reasons leading a not efficient remyelination mechanism. 
Remyelination failure can be divide in two distinct phases: (1) impaired recruitment of OPCs 
into lesions and (2) an inability to differentiate or mature into remyelinating oligodendrocytes 
[199, 200]. For example, CSPGs (chondroitin sulfate proteoglycans) inhibit the recruitment of 
OPCs by attenuating their migration and harming the morphological differentiation of 
oligodendrocytes [201, 202]. However, oligodendrocyte differentiation and myelination in 
culture are facilitated by achieving a sufficient OPC density [203], so the incapacity of OPCs 
to differentiate in MS plaques lesions could be related to an insufficient density within those 
lesions. Differentiation failure occurs also because chronically demyelinated MS lesions are 
associated with a low density of mature oligodendrocytes [204, 205]. 
Strategies that help to promote the proliferation and/or recruitment of OPCs within the 
demyelinated lesion in the CNS is an important therapeutic goal [206]. Several studies have 
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identified compounds that promote the recruitment, survival and differentiation of 
oligodendrocytes that could lead to an improved remyelination (Fig. 15). Benztropine, 
clemastine, quetiapine and GSK239512S target either muscarinic acetylcholine receptors (such 
as M1) and/or histamine receptors (such as H1 and H3). Domperidone elevates prolactin levels, 
which improves remyelination through prolactin receptor (PRLR). Other medications act 
through specific nuclear receptors: clobetasol activates glucocorticoid receptor (GR), IRX4204 
is a retinoid X like receptor (RXR) agonist, liothyronine stimulates thyroid hormone receptor 
(THR) and vitamin D activates vitamin D receptor (VDR). XAV939 and indomethacin both 
attenuate inhibitory WNT–β-catenin signalling. AXIN, axis inhibition protein; FZD, Frizzled. 
 
 
Figure 15. Drugs that affect myelin reformation and are prospective medications for repair in 
multiple sclerosis. Adapted from Plemel et al, 2017 [206]. 
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One additional factor that severely affects remyelination is the presence of an immune response 
following demyelination. The robust clearance of myelin debris is crucial following the 
degenerative phase [136, 207]; it was observed that when the myelin debris clearance is 
prevented owing to an impaired phagocyte response, then remyelination is slowed [208-210]. 
T cells, macrophages or microglia can damage OPCs and oligodendrocytes through 
mechanisms that include the release of free radicals, granzyme B and inflammatory cytokines 
[211]. In the other hand, immune cells also can produce a variety of growth factors that promote 
OPC recruitment and differentiation [212].  
 
As mentioned above, in MS activated myelin-reactive T cells are recruited leading to the 
activation of microglia and to the recruitment of circulating macrophages. Fingolimod, a 
structural analog of sphingosine, is converted in vivo to fingolimod-P, a structural analog of 
S1P, which acts as a nonselective agonist for S1P1, S1P3, S1P4, and S1P5 receptors, causing 
the irreversible internalization and degradation of bound S1P receptors; this preventing their 
recycling back to the cell surface and the consequently recruitment of T cells.  
An alternative therapeutic approach is the use of CNS reactive antibodies to promote 
remyelination [213, 214].  LINGO1, a membrane-bound protein, is one of the numerous 
molecules present in the lesion environment that have been identified to be impediments to 
OPC differentiation and thus potential remyelination inhibitors. Overexpression of LINGO1 in 
oligodendrocytes, axons [215] or astrocytes inhibits oligodendrocyte maturation via homotypic 
trans-interaction [216], meaning that LINGO1 in the lesion microenvironment can interact with 
oligodendrocyte LINGO1 to stall remyelination. Neutralization of LINGO-1 using anti-LINGO 
IgG antibodies has been found to promote remyelination in several animal models [217].  
Another group of identified remyelination promoting antibodies, including rHIgM22, have 
natural autoreactive antibodies (NAbs) features and they are generally of the IgM isotype. These 
antibodies react to self antigens and, bind them with rather low affinity but high avidity, 
compared to conventional antibodies [218]. In addition, all remyelination promoting antibodies 
with identified antigens are polyreactive, as a result of their flexible antigen-binding site. 
Several of these monoclonal antibodies (mAbs) recognize not only protein antigens but also at 
least one or multiple sphingolipids. Since only the hydrophilic carbohydrate moiety of the 
sphingolipids is exposed to the cell surface, it is detectable by antibodies, therefore, it is truthful 
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not consider the lipid backbone as essential part of the antigen. Currently the most widely 
accepted hypothesis concerning the remyelination-promoting antibodies mAbs is the lipid-raft 
hypothesis: mAbs targeting SLs stabilize existing rafts or stimulate the formation of new lipid 
rafts at the plasma membrane, thereby enhancing the effects of extracellular stimuli via existing 
cellular signaling pathways [219]. The discovery of these molecules highlights a number of 
promising approaches to improve remyelination for people with MS.  
 
Proposed mechanism of action of remyelination-promoting IgM  
All identified remyelination-promoting antibodies have germline origin or near germline with 
few somatic mutations, thus all cardinal features of NAbs and represent a subclass of NAbs.  
The discovery of natural antibodies for CNS reparative was serendipity. The first successful 
attempt to stimulate remyelination using NAbs was performed in the Theiler’s murine 
encephalomyelitis virus (TMEV)-induced model of demyelination by Rodriguez et al.  in 1987 
[220]. To test the hypothesis of virus-induced autoimmunity TMEV-infected SJL mice were 
immunized with spinal cord homogenates (SCH) of normal mice in order to stimulate a 
polyclonal antibody response directed against a variety of CNS antigens, including myelin 
components. Instead of an expected exacerbation of the disease course, mice immunized with 
SCH showed four-times’ higher levels of remyelination than non-immunized mice. These 
results demonstrated for the first-time a beneficial effect of antibodies in stimulating CNS 
remyelination. In particular, two monoclonal mouse antibodies of the IgM isotype (SCH79.08 
and SCH94.03) proved effective in promoting remyelination [221]. and both antibodies were 
able to target mature oligodendrocytes (OLs) in vitro. In order to identify monoclonal 
remyelination-promoting antibodies of human origin from sera of patients with monoclonal 
gammopathies, cerebellar slice cultures were used in addition to cultured OLs for preliminary 
screening [214]. This resulted in the identification of two serum-derived human remyelination-
promoting antibodies, sHIgM22 and sHIgM46, then engineered to make a recombinant 
antibody (rHIgM22 and rHIgM46) [48,49]. rHIgM22 has recently been approved by the FDA 
for Phase I, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study 
designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of single IV 
administrations of rHIgM22 in patients with all clinical presentations of MS.  
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Although to date the mechanism of remyelination is not entirely known, what is established is 
that rHIgM22 is capable to access to the brain. It has been generally accepted that IgMs with a 
molecular weight of close to 1 million are too large to cross the blood brain barrier (BBB) from 
the circulation to enter the CNS ([222]. Direct evidence of IgM access to the brain comes from 
a MRI study using antibodies labeled with ultra-small superparamagnetic iron oxide particles 
(USPIO) [223]. While MRI imaging showed a co-localization of rHIgM22 with demyelinating 
lesions in mice spinal cords in Theiler’s virus- infected mice, no IgM accumulation in the CNS 
was apparent in non-infected animals or animals without demyelination. In addition, 
dysfunction of the BBB is a typical feature of MS [224, 225] therefore, it is plausible to accept 
IgM access to demyelinated brain lesions as well in the human situation.  
Despite mouse and human remyelination-promoting IgMs stimulate repair in TMEV- and 
lysolecithin-demyelinated mice [214, 221, 226-230], the precise mechanism of action is still 
unknown.  Several pieces of evidence suggest that the rHIgM22 inhibits apoptotic signaling in 
OPCs and the differentiation of them to mature (MBP+, MOG+) OLs in vitro [231], promoting 
OPC survival and proliferation [232, 233]. The signaling complex responsible for the anti-
apoptotic effect consists of platelet-derived growth factor receptor alpha (PDGF!R), integrin 
avb3 and the Src family kinase (SFK) Lyn [231] (Fig. 16). PDGFaR is a phenotypic marker of 
OPCs [234] and retinal astrocytes [235] and its ligand, PDGF, is produced by neurons [236] 
and astrocytes as PDGF-AA [237] and -AB dimers [238]. Since OPC-signaling complex 
responsible for rHIgM22-mediated actions including PDGF receptor [231], this suggests an 
involvement of PDGF. Literature data shows that PDGF stimulates OPC proliferation and 
survival in vivo [239-241] and in vitro [241-244], but does not mediate survival in cells of the 
OL-lineage that are more mature than OPCs.  Most likely PDGF is required for rHIgM22-
mediated inhibition of apoptotic signaling and differentiation in isolated OPC cultures. In fact, 
rHIgM22-mediated OPC proliferation is detectable only in mixed glial cultures (cultures 
containing substantial amounts of astrocytes, microglia and OPCs) but not in highly enriched 
OPC populations [233]; secreted astrocytic or microglial factors, or direct cellular contact 
between OPCs and other glia seems to be essential for the proliferative response. Considering 
that PDGF is secreted by astrocytes and possibly microglia [237, 238] but not by 
oligodendrocyte-lineage cells, it demonstrates an involvement of cells other than OLs in IgM-
mediated OPC proliferation and, possibly, remyelination. It appears that three cell types (OPCs, 
microglia and astrocytes) are required for IgM stimulated proliferation of OPCs in vitro. The 
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growth factor PDGF and potentially other secreted microglial and astrocytic factors are 
important mediators for this effect.  
Although it is clear that the rHIgM22 promotes OPC survival and proliferation, the actual target 
and cellular type involved in rHIgM22-mediated action are still under investigation. Several 
pieces of evidence suggest that the antigen recognized by this antibody might be a plasma 
membrane lipid and that the binding target of rHIgM22 could be associated with detergent-
resistant membranes (DRM)/lipid rafts organization [245, 246]. This hypothesis is based on the 
observation that the well known anti-sulfatide antibody O4 and rHIgM22 have a similar binding 
pattern to CNS tissues [245], and that binding of rHIgM22 is abolished in CNS tissue sections 
from CST (-/-) mice [246], suggesting that likely sulfatide might represent a critical player in 
rHIgM22 biological activity.  
 
 
Figure 16. Proposed mechanism of action of rHIgM22. Binding of rHIgM22 to the surface of 
oligodendrocyte determines a reorganization of the membrane, favoring the interaction of Lyn, integrin 
αvβ3 and PDGFαR. IgM-stimulated activation of Lyn, with consequent activation of ERK 1/2 
determines the inhibition of the apoptotic pathway and of OPC differentiation. Other factors (e.g. PDGF) 
might be required to promote the proliferation of these cells. Adapted from Watzlawik et al, 2013 [219].  
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Treatments for MS have come a long way over the last two decades.  All of these drugs act by 
reducing the immune attack, which causes inflammation and damage to the myelin coating around 
nerve cells in the brain and spinal cord. Although these drugs can reduce damage to myelin, they 
can’t arrest it completely or repair the injury. Although the body, via remyelination, can replace 
damaged myelin, this process is impaired in MS. Remyelination, the physiological response after 
most demyelinating conditions, is a regenerative process whereby demyelinated axons are 
ensheathed with new myelin sheaths; it occurs through the activity of OPCs that migrate into 
damage sites [199]. This repair process is characteristic of the early disease phase of MS [247]; 
however, in late phase of MS, remyelination seems to be limited by oligodendrocyte density, which 
could be the product of a deficient oligodendrocyte recruitment [200]. When the remyelination 
fails, the axon, devoid of its myelin sheath, undergoes several physiological changes, resulting in 
axonal dysfunction, degeneration, and loss of sensory and motor function [248]. Treatments which 
promote remyelination would offer the potential to delay, prevent or reverse disability and a great 
deal of research is exploring this.   
One of the therapeutic approaches that is currently being developed to improve the remyelination 
involves the use of CNS reactive antibodies to promote remyelination [227]. One of these 
antibodies is rHIgM22, a recombinant form of a human IgM, which is able to bind to myelin and 
to the surface of mature, O4-positive oligodendrocytes in vitro [214], to enhance remyelination in 
three different mouse models of demyelination [214, 226, 227, 249, 250] and to promote OPC 
proliferation. Recently,  this antibody has completed a Phase 1a/b clinical trial in adults with both 
stable and active MS [251]. Despite the encouraging clinical data, the exact mechanism of action 
of rHIgM22 remains to be elucidated.  
 
The aim of this study is to identify the molecular binding target(s) of rHIgM22 and to identify the 
target cell(s) within CNS, in order to better understand the in vivo remyelination capability of 
rHIgM22. The binding target of rHIgM22 in oligodendrocytes and myelin could be represented by 
a complex that includes glycolipids, likely sulfatide, and could be associated with plasma 
membrane lipid rafts. In fact, the anti-sulfatide antibody O4 and rHIgM22 have a similar binding 
pattern to CNS tissues [245], and in both cases binding is abolished in CNS tissue sections from 
CST knock-out mice [246]; this suggests that the antigen(s) recognized by rHIgM22 could be a 
CST-sulfated antigen present in myelin and on the surface of differentiated OLs.  
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In addition, rHIgM22 has been shown to bind directly to differentiated OLs but binding to 
immature OPCs has not been detected, therefore no rHIgM22 effects have been observed in these 
cultures [227, 252]. Since OPCs apparently do not respond to rHIgM22, and differentiated 
oligodendrocytes are unlikely to be sufficient for substantial remyelination, it is likely that other 
cells are involved in remyelinating processes. Indeed, rHIgM22 seems to induced OPC 
proliferation by activating PDGFαR in mixed glial cultures, but not in isolated OPCs, suggesting 
that the stimulation of OPC proliferation by rHIgM22 requires factors produced by astrocytes [253] 
and/or microglia [233]. 
 
Defining the identity of the binding partners, the molecular organization of their membrane 
microenvironment and to identify the cell types with which rHIgM22 interacts should greatly 
contribute to the elucidation of the signaling mechanisms underlying the biological activity of 
rHIgM22. In addition, the characterization of the mechanism and the factors involved in the 
proliferation, recruitment, and differentiation of oligodendroglial progenitor cells is key in 
designing strategies to improve remyelination in demyelinating disorders. This, in turn, would 
allow to gain a better knowledge regarding the molecular mechanisms involved in MS etiology 
thus allowing to define new potential therapeutic targets. 
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Materials— Ca2+ and Mg2+-free HBSS, D-Glucose, BSA fraction V, trypsin, HEPES, phosphate-
buffered saline (PBS), poly-D-lysine, poly-L-lysine, Na3VO4, NaOH, Na2HPO4,CHCl3, CH3OH, 
polyisobuthylmethacrylate, O-phenylenediamine (OPD), H2O2, citric acid, HCl, sucrose, Tris-HCl, 
DOPC (1,2-Dioleoyl-sn-glycero-3-phosphocholine), n-octyl-β-D-glucoside, bovine serum 
albumin (BSA) were purchased from Sigma Aldrich;  DMEM:F12, StemPro Neural Supplement, 
StemPro Accutase were purchased from Invitrogen); DNaseI from Roche Spa; EGF, PDGF-AA, 
FGF-2 were purchased from Peprotech; NH4OH was purchased from Riedel-de Haën™; 
penicillin/streptomycin, DMEM High glucose, bovine fetal serum (FBS), glutamine were 
purchased from Euroclone Spa; MgSO4, CaCl2, 4-Methoxybenzaldehyde (anisaldehyde), HPTLC 
and Silica gel 60 (0.040-0.063 mm) were purchased from Merck; CH3COOH was purchased from 
Fluka; HPA sensor chips and HBS-N Buffer were purchased from GE Healthcare Srl. Chrompure 
Human IgM was purchased from Jackson Immuno Research, Inc. and HRP-conjugated anti-Human 
IgM μ-chain antibody was purchased from Thermo Fisher Scientific, Inc. Pure galactosylceramide 
(GalCer), sulfatide, phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine 
(PS) and phosphatidylinositol (PI) were purchased from Avanti Polar Lipids; DOPC, 
sphingomyelin (SM), and phosphatidic acid (PA) were purchased from Sigma Aldrich. 
Lysosulfatide was purchased from Matreya. Gangliosides (GM3, GM2, GM1, GD3, GD1a, GD1b, 
GT1b), glucosylceramide (GlcCer), glucosylsphingosine (GlcSph), and lactosylceramide (LacCer) 
were synthesized or purified in our laboratories.  
 
Animal specimens— For the experiments reported in this thesis, the sources of animal specimens 
were:  
• wild type (WT) C57BL/6N mice and acid sphingomyelinase knock-out (ASM(-/-)) mutant 
C57BL/6N mice [254], used for brain lipid extraction, myelin purification and preparation of mixed 
glial cultures;  
• primary cultured rat oligodendrocytes positive for rHIgM22 staining (kindly prepared by Dr. 
Yana Zorina, Acorda Therapeutics, Ardsley, NY);  
• primary cultured rat microglia [255], kindly provided by Dr. Michela Matteoli, Department of 
Medical Biotechnology and Translational Medicine, University of Milano;  
• hemibrains from wild type and cerebroside sulfotransferase (CST) (+/-) and (-/-) mice [162], 
kindly provided by Dr. Xianlin Han, Sanford-Burnham Medical Research Institute, FL, USA.  
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Mixed glial cell (MGC) culture— A primary mixed glial culture, composed of astrocytes, 
oligodendrocytes, and microglia, is obtained when newborn disaggregated cerebral brain cells from 
rat or mouse are plated at high cell density in serum-supplemented medium[233, 256]. In this 
culture model, neurons fail to survive and, after one week, mixed glial cell cultures are free of 
neurons, meningeal cells, and fibroblasts. MGC cultures were prepared according to Watzlawik et 
al [233]. Briefly, the hemispheres from P2 mice brains were minced with a surgical blade and then 
incubated for 30’ at 37°C in 0.05% trypsin in modified HBSS (Ca2+ and Mg2+ free HBSS containing 
5 g/L D-glucose, 3 g/L BSA fraction V, 20 mM HEPES, 100 U/mL penicillin and 100 μg/mL 
streptomycin). Following the addition of MgSO4 and DNase I, the sample was centrifuged at 200 
g at 8°C for 5 minutes and resuspended in modified HBSS. The tissue was then further dissociated 
by trituration through a sterile flame narrowed glass pipette, centrifuged at 200 g at 8°C for 10 
minutes, resuspended in culture medium and plated on Petri dishes or T75 flasks coated with poly-
D-lysine (25 μg/mL).  The cells were cultured in DMEM high glucose containing 10% heat 
inactivated FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 1 mM sodium pyruvate, and 2 
mM glutamine and the culture medium is changed every 3/4 days. With this protocol it is possible 
to obtain cultures with about 60-70% of astrocytes, 30- 40% of OPCs, and less than 3% of 
microglial cells.  
 
Oligodendrocytes isolation—Oligodendrocytes were harvested, through shaking procedure, from 
8-10 days old mixed glial cell cultures, prepared as described in the previous paragraph, when the 
cells were mostly immature, containing progenitor cells and immature oligodendrocytes. Briefly, 
microglia and dead cells are removed with a 30-minute shake at 37°C, 150 rpm in Corning® LSE™ 
Benchtop Shaking Incubator. After an 18-20 hour shaking to detach oligodendrocytes, the cell 
suspension was plated twice on untreated, non-TC, dishes to further remove microglia and 
astrocytes, before being centrifuged for 10 minutes at 8°C, 850 rpm. The surnatant was discarded 
and the pellet resuspended in OPC proliferative medium (DMEM:F12 1:1 containing 2 mM 
glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, 2% StemPro Neural Supplement, 10 
ng/mL EGF, 10 ng/mL PDGF-AA, 10 ng/mL FGF-2). Media was replaced every 3/4 days and cells 
were carried using Accutase. The cells obtained with this method are mostly immature 
oligodendrocytes. To obtain mature oligodendrocytes, differentiation medium containing 40 mM 
T3 was added to the cultured OPCs. Mixed glial cell culture that underwent a shaking procedure 
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to isolate oligodendrocytes precursors were used maximum three times. After the third time, the 
adherent layer was represented mostly by astrocytes, thus allowing to collect these cells. The 
collected cells were then stored at -80°C, before being lyophilized and subjected to lipid extraction.  
Myelin isolation— Purification of myelin from mouse brain was performed using an optimized 
version of the protocol described in [257]. Frozen brains from C57BL/6N wild type mice ranging 
from 2 to 4 months of age were thawed at room temperature (RT) before removing the cerebellum 
and the meningeal membranes. 50 mg of tissue were suspended in 500 μL of 0.25 M sucrose in 10 
mM Tris-HCl, pH 7.4 and Dounce homogenized (10 strokes, tight) before being centrifuged at 500 
g, 4°C for 10 minutes. The supernatant was collected and further centrifuged at 21000 g, 4°C for 
10 minutes with Ultra-centrifuge Beckman TL- 100. The supernatant was discarded and the pellet 
was resuspended in 500 μL of 0.25 M sucrose in 10 mM Tris-HCl, pH 7.4 and then layered on top 
of 1250 μL of 0.88 M sucrose in 10 mM Tris-HCl, pH 7.4. After this, the samples were centrifuged 
at 21000 g, 4°C for 10 minutes to separate the mitochondria from the myelin vesicles. In fact, 
myelin will float on the surface whereas the denser mitochondria will pellet at the bottom of the 
tube. The myelin vesicle layer was carefully recovered, resuspended in an equal volume of ice-cold 
water and then centrifuged at 21000 g, 4°C for 10 minutes. After discarding the supernatant, the 
pellet was resuspended in 500 μL of 0.25 M sucrose in 10 mM Tris- HCl, pH 7.4, layered on top 
of 1250 μL of 0.88 M sucrose in 10 mM Tris-HCl, pH 7.4 and centrifuged at 21000 g, 4°C for 10 
minutes in order to separate myelin from membrane debris. The myelin layer was carefully 
recovered, resuspended in an equal volume of ice-cold water and then centrifuged at 21000 g, 4°C 
for 10 minutes. The supernatant was discarded and the pellet was resuspended in 120 μL of ice-
cold water. Protein content was determined with DC protein assays (Bio-Rad).  
 
Sample preparation— Frozen brains from wild type (WT) C57BL/6N mice and acid 
sphingomyelinase knock-out (ASM(-/-)) mutant C57BL/6N mice were thawed at room 
temperature (RT). Meninges were removed, the brains were minced with a surgical blade, 
resuspended in ice-cold water and subjected to sonication. The samples were then Dounce 
homogenized (10 strokes, tight) before being snap frozen and subsequently lyophilized.  
Frozen rHIgM22-positive rat oligodendrocytes were thawed at RT, resuspended in ice-cold water, 
snap frozen and then lyophilized. Cultured oligodendrocytes were collected after washing the 
flasks and/or petri dishes twice with PBS containing 1 mM Na3VO4. The cells were scraped twice 
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in PBS containing 1 mM Na3VO4 and centrifuged at 3000 rpm, 4°C for 5 minutes. The supernatant 
was discarded, the pellet was resuspended in ice-cold water, snap frozen and lyophilized.  
Myelin, prepared from mouse brain following the procedure described in the previous paragraph, 
was snap frozen and lyophilized. 
 
Total lipid extraction, phase partitioning and alkali treatment— Lipids from the lyophilized 
samples were extracted with CHCl3:CH3OH:H2O 20:10:1 (v/v/v) and subjected to a modified two-
phase Folch’s partitioning to obtain the aqueous (Aq. Ph.) and the organic phases (Or. Ph.) [258]. 
In brief, 1550 μL of the solvent system were added to the lyophilized samples. The samples were 
then mixed at 1100 rpm, RT for 15 minutes and centrifuged at 13200 rpm, RT for 15 minutes. The 
supernatant was collected as Total lipid extract (TLE) and the extraction was repeated again twice 
by adding the 1550 μL of the solvent system to the pellets. The pellets were air dried and 
resuspended in 1M NaOH and incubated overnight at RT before being diluted with water to 0.05M 
NaOH to allow the determination of the protein content with DC assay. Aliquots of the TLE were 
then subjected to phase partitioning adding either 20% of water by volume. The samples were then 
mixed at 1100 rpm, RT for 15 minutes and centrifuged at 13200 rpm, RT for 15 minutes. The Aq. 
Ph. were recovered, and CH3OH:H2O 1:1 (v/v) were added to the organic phase before mixing the 
samples at 1100 rpm, RT for 15 minutes and centrifuging at 13200 rpm, RT for 15 minutes. The 
new aqueous phases were recovered and united to the ones previously collected. The organic 
phases were dried under N2 flux and resupended in a known volume of CHCl3:CH3OH 2:1 (v/v). 
Aliquots of the organic phases were then subjected to alkali treatment to remove 
glycerophospholipids [258]. 
 
Chromatography 
Chromatography is an important biophysical technique that allows the separation, identification, 
and purification of the components of a mixture for quantitative and qualitative analysis [151]. The 
word “chromatography”, used by Tswett in 1906, derived from the Greek words chroma (color) 
and graphien (to write) and it is defined as: “A physical method of separation in which the 
components to be separated are distributed between two phases, one of which is stationary 
(stationary phase) while the other (the mobile phase) moves in a definite direction.” 
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There are different types of chromatography but they all work on the same principle; all 
chromatographic systems have a mobile and a stationary phase: sample is dissolved in the mobile 
phase, which travels through the stationary phase. Separation is possible because different 
compounds have different affinities for the mobile and stationary phases, thereby affecting their 
distribution between the two phases. 
Chromatographic methods are classified according to mobile phase, stationary phases, separation 
mechanism or type of support. The mobile phase may be either a gas (GC, Gas Chromatographic) 
or liquid (LC, Liquid Chromatographic); the stationary phase may be a liquid or, more usually, a 
solid. Table 2 summarizes some of the chromatographic methods that have been developed on the 
basis of different mobile–stationary phase combinations. 
 
By state of phases and mechanism 
Mobile phase Stationary phase Acronym Mechanism 
Gas Solid GSC Adsorption Chromatography  
Liquid GC Partition Chromatography 
Liquid Solid LSC Adsorption Chromatography 
Liquid LC Partition Chromatography 
Liquid  CE Electromigration 
 
By the polarity of phases 
 Stationary phase Mobile phase  
Normal phase 
Chromatograpy 
More polar Less polar LC 
Normal phase 
Chromatograpy 
Less polar More polar LC 
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By geometry of the separation region 
Planar 
Chromatograpy 
2-dimensional 
Column 
Chromatography 
1-dimensional 
 
Table 2. Chromatographic methods. 
 
The chromatographic procedures used to identify the antigen recognize by rHIgM22 are discussed 
in the next section. 
 
Thin-layer chromatography 
Thin layer chromatography (TLC) is the easiest way to analyze the total lipid mixtures extracted 
from tissues and cultured cells. 
In TLC the stationary phase is a thin layer of a solid such silica supported on an inert base such as 
glass o aluminum foil. The mixture is applied at the bottom of the TLC plate and allowed to dry, 
then the plate is placed in a closed tank containing solvent (the mobile phase) so that the liquid 
level is below the spot (Fig. 17).  
This method allows to have an economical first information about the possible structure of the 
separated molecules on the basis of their chromatographic mobility in comparison with standards 
and of their reactivity to the staining procedures [258, 259]. 
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Figure 17. Development of a TLC plate. An orange spot separates into a red and yellow spot. 
 
TLC Procedure. Lipids and samples were separated using HPTLC plate (silica gel 60 HPTLC, 
Merck): the samples were spotted on a 3 mm imaginary lane at 1.5 cm from the plate bottom edge 
and were applied maintaining a 3–5 mm distance. The plate was immersed into the 
chromatographic solvent system (1 cm deep) and put in a closed tank allowing the solvent to reach 
the TLC top edge (TLC size, 10×10 cm or 10x20 cm). Chromatography was carried out at room 
temperature in the range of 20–25°C. Depending on the samples to be analyzed, the following 
solvent systems have been used:  
• CHCl3:CH3OH:H2O 110:40:6 (v/v/v) for the analysis of pure sulfatide, lysosulfatide, neutral 
glycolipids, pure phospholipids, total lipid extracts, organic phases and methanolized organic 
phases;  
• CHCl3:CH3OH:0.2% CaCl2 in H2O 50:42:1 (v/v/v) for the analysis of pure gangliosides and 
aqueous phases;  
• CHCl3:CH3OH:CH3CH(OH)CH3:H2O 70:20:5:3 (v/v/v/v) for the analysis of column 
chromatography fractions; 
 
After separation, lipids were detected by spraying the TLC plates with Anisaldehyde reagent for 
the general detection of lipids.  
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Figure 18. Schematic representation of the analytical pathways for complex lipids TLC. Adapted from 
Scandroglio et al, 2009 [258].  
 
TLC immunostaining  
TLC immunostaining is a simple, rapid and sensitive method for the detection of antigenic targets 
of antilipid antibodies; as described by Magnani et al. [259], the procedure consists in two essential 
steps: separation of lipids on a TLC plate and detection of lipids in situ with specific antibodies 
(Fig. 19).  
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Figure 19. TLC overlay assay schemes of antibody-mediated GSL detection. Adapted from Meisen et 
al, 2011 [260].  
 
TLC immunostaining Procedure. After chromatographic separation (as described above), the TLC 
plates were coated three times with a polyisobuthylmethacrylate solution [258], and air dried for 1 
hour before being immersed in blocking solution (3% BSA in PBS) for 1 hour.  After washing 
thrice (1 min each) with washing buffer (PBS), the plates were then incubated with rHIgM22 or 
isotype human IgM (Chrompure Human IgM; Jackson Immunoreasearch; negative control) at 0.5, 
1.0, 2.5 or 5.0 μg/mL in 1% BSA in PBS overnight at 4°C. After the incubation with the primary 
antibody, the plates were washed three times and incubated with an HRP-conjugated anti-Human 
IgM μ-chain antibody for 1 hour, RT, and developed using O-phenylenediamine (OPD)/H2O2 in 
0.05 M citrate-phosphate buffer pH 5. 
 
Column Chromatography  
Column chromatography allows to separate a mixture into the pure individual components, to 
remove impurities and to identify unknown compounds. In column liquid chromatography, the 
mobile phase is liquid (an organic solvent or a mixture of solvents) and the stationary phase (silica 
or alumina) can be either solid or liquid supported by an inert solid. The stationary phase is packed 
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into a column (glass or metal); its length and diameter vary by the amount of sample to be analyzed, 
the separation mode to be used, and the degree of resolution required. There are two procedure to 
prepare the column by packing with silica: dry or wet method.  In dry method the column is filled 
with dry powdered silica and then the mobile phase is flushed through it until all the silica is evenly 
wet (equilibrated). The sample is dissolved in a small volume of mobile phase and it is applied at 
the top of the column. Classical or low- pressure chromatography utilizes gravity flow or a 
peristaltic pump to maintain a flow of eluent (mobile phase) through the column.  Flash 
chromatography is an alternative to gravity-fed chromatography and it is a rapid with high 
resolution technique. It utilizes smaller silica gel particles (250-400 mesh) and for this reason it 
needs at pressurized gas (i.e. nitrogen gas) to restricted flow of solvent caused by the small gel 
particles. 
 
Column Chromatography Procedure. The aqueous phase from WT mouse brain (~ 30 mg) was 
purified by flash chromatography with silica gel 60 column (1 cm, internal diameter, with 20 cm 
of Silica gel 60, 0.040-0.063 mm) equilibrated and subsequently eluted with 
CHCl3:CH3OH:CH3CH(OH)CH3:H2O 70:20:5:3 (v:v:v:v). The eluting solvents and the lipids 
obtained in each eluate were collected as fractions, each with a volume of 3 mL. TLC is then used 
to determine which fractions contain the compound. The structural analysis of the purified lipids 
was performed by ESI-MS. 
 
Electrospray Ionisation Mass Spectrometry (ESI-MS)  
Mass spectrometry is an analytical technique used to identify unknown compounds within a 
sample. The process consists in the conversion of the sample into gaseous ions which are then 
characterized by their mass to charge ratios (m/z). The mass spectrometry experiment consists in 
(1) the ionization of molecules in the gaseous phase, in (2) the separation of the different ions 
according to their specific mass to charge ratio (m/z) and in (3) their detection. For this reason, the 
mass spectrometry instrument consists of three major components: (1) ion source, for producing 
gaseous ions from the sample under investigation; (2) analyzer, for resolving the ions into their 
characteristics mass components according to their mass-to-charge ratio; (3) detector system, for 
detecting the ions and recording the relative abundance of each of the resolved ionic species (Fig. 
20). 
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Figure 20. Basic components of the ESI-mass spectrometer. 
In ESI-mass spectrometer, electrical energy is used to assist the transfer of ions from solution into 
the gaseous phase by protonation or cationisation. The transfer of ionic species from solution into 
the gas phase by ESI involves three steps: (1) dispersal of a fine spray of charge droplets, followed 
by (2) solvent evaporation and (3) ion ejection from the highly charged droplets [261] (Fig. 21). 
 
 
 
Figure 21. A schematic representation of the ESI-ion source. Adapted from Banerjee et al, 2012 [262]. 
 
The molecular ions produced in the ionization chamber are then transferred in the mass analyzer 
region via several ion optics (electromagnetic elements like skimmer, focusing lens, multipole, 
etc.). The mass analyzer separates the ions according to their m/z value. The separated ions are then 
passed to the detector systems to measure their concentration, and the results are displayed on a 
chart called a mass spectrum. The ions in the gas phase are very reactive and often short lived; for 
 57 
this reason, the ion optics, analyzer and the detectors are kept at very high vacuum (typically from 
10-3 torr to 10-6 torr pressure).  
Tandem mass spectrometry, also known as MS/MS, involves multiple steps of mass spectrometry 
selection.  It is a technique to break down selected ions (precursor ions) into fragments (product 
ions). The fragments then reveal aspects of the chemical structure of the precursor ion. Once 
samples are ionized by ESI to generate a mixture of ions, a precursor ion of a specific m/z is selected 
(MS1) and then it is fragmented (MS2) applying a voltage 30-50 times higher than the previous 
one to generate a product ion for detection. 
 
ESI-MS Procedure. The analyses of the compound were carried out using a ThermoQuest Finnigan 
LCQ Deca ion-trap mass spectrometer (Finnigan MAT, San Jose, CA) equipped with an 
electrospray ionization (ESI) ion source, an Xcalibur data system, and a TSP P4000 quaternary 
pump. The conditions for MS analysis, in negative mode, were the following: sheath gas flow, 50 
arbitrary units; spray voltage, 4 kV; capillary voltage, -47 V; capillary temperature, 260°C; and 
fragmentation voltage (used for collision- induced dissociation), 50%.  
 
Surface plasmon resonance 
Surface plasmon resonance (SPR) is an optical technique utilized for detecting molecular 
interactions. Binding of a mobile molecule (analyte) to a molecule immobilized on a thin 
metal film (ligand) changes the refractive index of the film [263].  
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Figure 22. Binding of peptides onto the immobilized lipids (HPA) surfaces in the BIACORE system. 
Adapted from Mozsolits at al, 2003 [264]. 
 
SPR represents a much more physiological experimental setting respect to the TLC 
immunostaining (where the lipids are adsorbed on a silica gel surface, not being organized as a 
lipid monolayer), and should allow to obtain information on the effect of the presence of other 
lipids on the ability of antibody to bind the target. 
The affinity of IgM22 for different purified lipids in supported lipid monolayers has been assessed 
using the sensor chip HPA (Fig. 22), which bears a flat hydrophobic surface consisting of long-
chain alkane thiol molecules attached directly to a gold film. Preformed liposomes adsorb 
spontaneously to the surface of the chip to form a supported lipid monolayer, with polar head 
groups directed out towards the solution containing the antibody.  
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Figure 23. The preparation of a monolayer and a bilayer model membrane system on an HPA sensor 
chip. Adapted from Mozsolits at al, 2003 [264]. 
SPR Procedure. The affinity of rHIgM22 for different purified lipids in supported lipid monolayers 
was assessed by SPR using a BIAcore 3000 analytical system (GE Healthcare, Uppsala, Sweden) 
with HPA sensor chips. Chips were incubated in the presence of DOPC  
liposomes containing different amounts of the target lipids. Liposomes containing the target lipids 
were prepared following standard procedures. Briefly, different amounts of sulfatide (1 – 0.1 – 0.01 
– 0.001 - 0.0005 μmol) in chloroform/methanol 2:1 were mixed with 1 μmol of DOPC, either alone 
or in presence of different amounts of a second lipid (cholesterol, GalCer, SM, lysosulfatide), and 
dried under N2 flux. The residue was then suspended in 200 μL HBS-N buffer (20 mM 4-(2-
hydroxyethyl)-1-piperizineethanesulfonic acid (HEPES) pH 7.4, 150 mM NaCl), mixed with a 
vortex mixer and sonicated for 15 minutes with a water bath sonicator. The solutions were then 
filtered using a 0.22 μm polyvinylidene difluoride (PVDF) syringe-driven filter unit. The sensor 
chip were pretreated with 40 mM n-octyl-β-D-glucoside and the liposome solutions were 
immobilized on the chip for 30 min at a flow rate of 2 μL/min, using HBS-N buffer without or with 
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1 mM CaCl2 and 1 mM MgSO4 as running buffer. The chip surface was then washed with 50 mM 
NaOH for 1 min at 5 μL/min, and blocked with 100 μg/ml bovine serum albumin (BSA) before 
proceeding with the analysis. For analysis, 5 μg/mL of rHIgM22 or control IgM were injected at a 
flow rate of 10 μL/min. Signals generated in a negative control cell without target lipid have been 
subtracted from the experimental values. Quantitative evaluation of the binding and dissociation 
reactions were performed using the software BIAevaluation version 3.1 [265].  
  
Statistical analysis  
Experiments were run in triplicate, unless otherwise stated. Data are expressed as mean 
value ± SD and were analyzed by one-way analysis of variance followed by Student-
Neuman-Keul’s test. p-values are indicated in the legend of each figure.  
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 62 
In vitro binding of rHIgM22 to purified lipids  
In order to identify the antigen(s) recognized by rHIgM22, we have tested the binding of rHIgM22 
to purified lipids in vitro using TLC immunostaining and surface plasmon resonance on lipid 
monolayers with different composition. 
 
Binding to sulfatide  
Data published by Rodriguez et al. demonstrated that rHIgM22 is able to bind to myelin and to the 
surface of oligodendrocytes in vitro [214, 246] and that it binds to CNS tissue sections with a 
pattern similar to that of O4, an anti-sulfatide antibody [245], suggesting that sulfatide could be 
one of the antigens recognized by this remyelination-promoting antibody.  
Starting from this observation, the first purified lipid we analyzed was sulfatide. Fig. 24 shows 
rHIgM22 binding to different amounts of pure sulfatide, from 0.05 to 10 nmol; the binding was 
proportional to the amount of sulfatide up to 10 nmoles. Increased binding was observed by 
increasing the concentration of antibody from 2.5 µg/mL to 5.0 µg/mL, however below 2.5 g/mL 
the binding was not quantitatively proportional to the antibody concentration. Binding was very 
weak at antibody concentrations of 1.0 µg/mL or lower. Significant binding was observed also for 
isotype IgM control; however, this binding was significantly lower than that of rHIgM22 in all the 
experimental points, except for the IgM concentration of 0.5 µg/mL. 
To confirm the specificity of rHIgM22 binding to sulfatide, we set up SPR experiments using lipid 
monolayers, an experimental setting that allows an antigen presentation closer to the one occurring  
in a biological membrane. 
As shown in Fig. 25, rHIgM22 at 5 g/mL binding to sulfatide in DOPC monolayers on HPA chip, 
at all the amounts of the target lipid (0.0005-1 mol), was significantly higher than the binding of 
control IgM. Moreover, the shape of the sensorgrams was consistent with a specific binding for 
rHIgM22. With a DOPC:sulfatide 1:0.01 molar ratio, the maximum response for rHIgM22 was 
two-fold higher than the maximum response for control IgM.  
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Figure 24. Thin layer chromatography (TLC) and TLC-immunostaining of purified sulfatide with 
rHIgM22. 
(A) Different amounts of purified sulfatide (from 0.05 to 10.00 nmol) were separated by TLC using 
CHCl3:CH3OH:H2O 110:40:6 (v/v/v) as solvent system and the chemical detection of lipid was carried out 
with Anisaldehyde reagent. (B) After chromatographic separation, TLC plates were fixed with a 
polyisobuthylmethacrylate solution and immunostained with different concentrations (0.5, 1.0, 2.5 and 5.0 
μg/mL) of the two primary antibody rHIgM22 and Human IgM (negative control) as described in 
“Methods”. (C) Optical density (OD) of each band was calculated by densitometry; the data are expressed 
as mean ± SD of three independent experiments. 
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Figure 25. Binding of rHIgM22 to sulfatide in DOPC monolayer.  
(A) Lipid monolayers were formed in HBS-N buffer as described in “Methods” from small unilamellar 
vesicles composed of DOPC (1 μmol) and different amounts of sulfatide (from 5×10-4 μmol to 1 μmol); 
the liposome solutions were immobilized on an HPA sensor chip. The ability to anchor sulfatide was then 
assayed by injections of rHIgM22 or Human IgM (5.0 μg/mL) at a flow rate of 10 μL/min across the 
different monolayers. (B) The binding of the two antibodies is represented also as maximum response; the 
data are expressed as mean ± SD of three independent experiments, * p<0.05 
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Binding to lysosulfatide  
The deacylated form of sulfatide, lysosulfatide, is present as a minor component in the normal CNS 
but its levels can be increased as a consequence of some pathological conditions, such as 
metachromatic leukodystrophy [266-268]. Considering that sulfatide and lysosulfatide bear the 
same 3-O-sulfo-galactose head group, the binding of rHIgM22 to lysosulfatide was analyzed. The 
binding to lysosulfatide was assessed using both TLC immunostaining and SPR experiments and, 
in both experimental settings, the antibody resulted able to bind the lipid. In TLC immunostaining 
assay, rHIgM22 was able to recognize lysosulfatide and the surface plasmon resonance 
experiments confirmed that these binding was specific (Fig. 26).  
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Figure 26. Thin layer chromatography (TLC) and TLC-immunostaining of purified lyosulfatide with 
rHIgM22. 
(A) Different amounts of purified lyosulfatide (from 0.05 to 10.00 nmol) were separated by TLC using 
CHCl3:CH3OH:H2O 110:40:6 (v/v/v) as solvent system and the chemical detection of lipid was carried out 
with Anisaldehyde reagent. After chromatographic separation, TLC plates were fixed with a 
polyisobuthylmethacrylate solution and immunostained with 5.0 μg/mL of the two primary antibody 
rHIgM22 and Human IgM (negative control) as described in “Methods”. The optical density (OD) of each 
band was calculated by densitometry; the data are expressed as mean ± SD of three independent 
experiments. (B) Lipid monolayers were formed in HBS-N buffer as described in “Methods” from small 
unilamellar vesicles composed of DOPC (1 μmol) and different amounts of lysosulfatide (0.1 μmol or 0.5 
μmol); the liposome solutions were immobilized on an HPA sensor chip. The ability to anchor lysosulfatide 
was then assayed by injections of rHIgM22 or Human IgM (5.0 μg/mL) at a flow rate of 10 μL/min across 
the different monolayers. (B) The binding of the two antibodies is represented also as maximum response; 
the data are expressed as mean ± SD of three independent experiments, * p<0.05 
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Binding to glycolipids  
The myelin membrane is enriched in glycolipids (31% vs. 7% for liver cell plasma membranes) 
[151], in particular galactosylceramide (~20% of total lipids) [154].  On the other hand, 
gangliosides, the most abundant glycosphingolipids in the nervous system, are a minor component 
of the myelin membrane (<1% of total lipids) [269]. So, using the previous experimental setting, 
other potential glycolipid targets have been screened.  
rHIgM22 at 5.0 g/mL showed no significant binding to sphingolipids such as GalCer, SM, LacCer 
(Fig. 27A), GlcSph and GlcCer (Fig. 27B) and mono- (GM3, GM2, GM1) and poly-
sialogangliosides (GD3, GD1a and GD1b) (Fig. 28). While control IgM at 5.0 g/mL showed no 
significant binding to GalCer, LacCer, SM, in the case of gangliosides the binding was slightly 
higher than binding of rHIgM22. 
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Figure 27. Thin layer chromatography (TLC) and TLC-immunostaining of neutral glycolipids with 
rHIgM22. 
(A) Different amounts of purified GalCer, LacCer and SM (from 0.05 to 10.00 nmol) or (B) GlcSph and 
GlcCer (from 2.00 to 8.00 nmol) were separated by TLC using CHCl3:CH3OH:H2O 110:40:6 (v/v/v) as 
solvent system and the chemical detection of lipid was carried out with Anisaldehyde reagent. After 
chromatographic separation, TLC plates were fixed with a polyisobuthylmethacrylate solution and 
immunostained with 5.0 μg/mL of the two primary antibody of the two primary antibody rHIgM22 and 
Human IgM (negative control) as described in “Methods”. 
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Figure 28. Thin layer chromatography (TLC) and TLC-immunostaining of purified gangliosides with 
rHIgM22. 
4.00 nmol of each purified gangliosides were separated by TLC using CHCl3:CH3OH:CaCl2 0,2% 
50:42:11 (v/v/v) as solvent system and the chemical detection of lipid was carried out with Anisaldehyde 
reagent. (B) After chromatographic separation, TLC plates were fixed with a polyisobuthylmethacrylate 
solution and immunostained with 5.0 μg/mL of the two primary antibody of the two primary antibody 
rHIgM22 and Human IgM (negative control) as described in “Methods”. 
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Binding to glycerophospholipids  
Since glycerophospholipids are the major component of biological membranes, the binding of 
rHIgM22 to glycerophospholipids was assessed through TLC immunostaining.  
Under experimental conditions similar to those used to assess binding to sulfatide, rHIgM22 
showed no significant binding to PC and a non-specific binding to PE (Fig. 29). rHIgM22, on the 
other hand, showed a significant binding to phosphatidic acid (PA), phosphatidylserine (PS) and 
phosphatidyinositol (PI); in this case, the control IgM gave no significant binding, suggesting that 
binding of rHIgM22 to these lipids might be specific.  
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Figure 29. Thin layer chromatography (TLC) and TLC-immunostaining of purified phospholipids 
with rHIgM22. 
Different amounts of purified PC, PE, PA, PS and PI (from 0.10 to 10.00 nmol) were separated by TLC 
using CHCl3:CH3OH:H2O 110:40:6 as solvent system and the chemical detection of lipid was carried out 
with Anisaldehyde reagent. After chromatographic separation, TLC plates were fixed with a 
polyisobuthylmethacrylate solution and immunostained with 5.0 μg/mL of the two primary antibody of the 
two primary antibody rHIgM22 and Human IgM (negative control) as described in “Methods”. 
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Effect of different lipids on the binding of rHIgM22 to sulfated containing 
monolayers 
 
Model membrane studies have shown that sulfatides are protected against antibody recognition in 
a sphingomyelin/cholesterol environment compared to a phosphatidylcholine/cholesterol 
environment, suggesting that also the binding of rHIgM22 could be affected by lipid 
microenvironment [270, 271]. 
Therefore, SPR experiments have been used also to analyzed the effect of the presence of a second 
lipid on rHIgM22 binding to sulfatide. In these experiments, monolayers were prepared by mixing 
a fixed amount of DOPC and a fixed amount of sulfatide (0.01 μmol) with a third lipid using molar 
ratios corresponding either to those found in the myelin membrane or to a 10 fold higher amount 
of the third lipid (Figure 20-21), reflecting the molar ratio expected for a lipid raft-like 
microenvironment.  
Binding analysis revealed that the binding response of rHIgM22 to sulfatide containing monolayers 
is reduced in the presence of either GalCer (0.66 or 0.066 μmol, the molar ratio calculated for 
GalCer:sulfatide in myelin and a 10-fold higher ratio, possibly resembling the situation in 
glycolipid-enriched membrane rafts) or cholesterol (0.1 μmol, at a molar ratio cholesterol:sulfatide 
0.1:0.01), while the addition of SM (0.12 μmol, at a molar ratio SM:sulfatide 0.012:0.01) to the 
monolayers determined a increase of the binding (Fig. 30). These finding suggest that the binding 
of rHIgM22 to sulfatide is affected by the membrane lipid microenvironment and that the presence 
of different lipids, at a certain density, might be required to allow an optimal recognition of the 
antigen by rHIgM22.  
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Figure 30. Effect of GalCer, Cholesterol and SM on rHIgM22 binding to sulfatide. 
(A) Lipid monolayers were formed in HBS-N buffer as described in “Methods” from small unilamellar 
vesicles composed of DOPC (1 μmol), a fixed amount of sulfatide (1×10-2 μmol) and different amounts of 
(A) GalCer (0.66 μmol or 0.066 μmol), (B) Cholesterol (0.1 μmol), (C) SM (0.012 μmol); the liposome 
solutions were immobilized on an HPA sensor chip. The ability to anchor lipid was then assayed by 
injections of rHIgM22 or Human IgM (5.0 μg/mL) at a flow rate of 10 μL/min across the different 
monolayers. 
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In vitro binding of rHIgM22 to lipid extracts  
Previous experiments were aimed at the individuation of the molecular target of the antibody, to 
better understand mechanisms underlying its activity. The data collected on purified lipids, show 
that rHIgM22 binds to sulfatide in vitro but it does not bind to other myelin sphingolipids, such as 
galactosylceramide, lactosylceramide and sphingomyelin. To verify whether rHIgM22 can bind 
sulfatide or other lipids in myelin extracts and other CNS cells, the binding of rHIgM22 was tested 
not only to purified lipids, but also to partially purified lipid extracts obtained from mice and rat 
brain, cerebellum, brain myelin, mixed glial cultures, microglial cells and cultured 
oligodendrocytes (listed in the Materials and Methods section). 
Total lipid extracts prepared under the experimental conditions described in Materials and Methods 
do contain all cellular lipids, including hydrophobic (cholesterol and triglycerides) and 
amphipathic lipids: glycerophospholipids and sphingolipids, and, among those, sphingomyelin, 
neutral glycosphingolipids (GlcCer, LacCer, and, in myelin and myelin-producing cells, GalCer), 
and acidic sphingolipids (gangliosides, enriched in neurons, and sulfatide, enriched in myelin).  
 
As shown in Fig. 31, when applied to total lipid extracts, the TLC immunostaining procedure was 
strongly affected by the binding of both rHIgM22 and control IgM to the glycerophospholipids, 
giving multiple signals whose intensity was not proportional to the amount of lipid samples. It was 
thus impossible, in these samples, to identify a signal surely ascribable to a specific binding to 
sulfatide (even if the amount of sulfatide theoretically present in these samples was comparable to 
the amount detectable using pure sulfatide using similar experimental conditions).   
Since in total lipid extracts from biological samples, glycerophospholipids are present in amounts 
much higher than sulfatide and sphingolipids, representing a significant source of interference in 
the TLC immunostaining procedure,  lipid extracts been subjected to a two-phase Folch's 
partitioning (with minor modifications), allowing to obtain aqueous phases enriched in 
gangliosides and a minor portion of sulfatide, and organic phases enriched in the more apolar lipids, 
including galactolipids and glycerophospholipids. 
To obtain lipid mixtures devoid of potentially interfering glycerophospholipids and enriched in 
sulfatide and other sphingolipids, the organic phases have been further treated with alkali in 
methanol; this treatment allows to remove almost completely the interfering glycerophospholipids 
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from the sample, obtaining organic methanolized phases, which is enriched in sulfatide and 
galactolipids.   
As shown in Fig. 32, in TLC immunostaining experiments for phospholipid-void methanolized 
organic phases it was clearly possible to detect a double band co-migrating with the sulfatide 
standard in samples from wt and ASMKO mouse brain, myelin and rHIgM22-positive cultured 
oligodendrocytes. All these samples showed a weak reactivity with the control IgM, however the 
ratio of the rHIgM22 signal and the control IgM signal was comparable to that observed for pure 
sulfatide. 
In TLC immunostaining experiments for aqueous phases, we observed rHIgM22-immunoreactive 
bands co-migrating with the pure sulfatide standard (Fig. 33) and a second rHIgM22-
immunoreactive band migrating below sulfated, co-migrating with the pure PI and PS standard, 
confirming the observation that the antibody is able to bind sulfatide, PI and PS.  
It is common to have a small contamination of these two lipids in the aqueous phase, but since PI 
and PS are glycerophospholipids, they are usually recovered in the organic phase; for this reason, 
the experiments showed in the next section were aimed to isolate phosphatidylinositol and 
phosphatidylserine species from aqueous phase in order to better understand the characteristics of 
these two glycerophospholipids. 
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Figure 31. rHIgM22 binding to total lipid extracts and organic phases. Using TLC immunostaining we 
assessed rHIgM22 binding to different total lipid extracts (TLE) and organic phases (O.Ph.) obtained from 
different cells and tissues such as mixed glial cells, wild type mouse brain, ASMKO mouse brain, rHIgM22 
positive OPC, and mouse myelin. For each extract and organic phase, either 150 μg protein were loaded on 
the TLC plates. The organic phases used for the analysis were obtained through partition. After 
chromatographic separation (solvent system: CHCl3:CH3OH:H2O 110:40:6), After chromatographic 
separation, TLC plates were fixed with a polyisobuthylmethacrylate solution and immunostained with 5.0 
μg/mL of the two primary antibody rHIgM22 and Human IgM (negative control) as described in “Methods”.  
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Figure 32. TLC-immunostaining of methanolyzed organic phases with rHIgM22. 
O.Ph.Met (amounts equivalent to 150 μg protein) obtained from different tissues, such as wild type mouse 
brain, ASMKO mouse brain, rHIgM22 positive OPC and mouse myelin were separated by TLC using 
CHCl3:CH3OH:H2O 110:40:6 (v/v/v) as solvent system. After chromatographic separation, TLC plates were 
fixed with a polyisobuthylmethacrylate solution and immunostained with 5.0 μg/mL of the two primary 
antibody rHIgM22 and Human IgM (negative control) as described in “Methods”. 
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Figure 33. rHIgM22 binding to aqueous phases in TLC immunostaining.  
Using TLC immunostaining we assessed rHIgM22 binding to aqueous phases (A.Ph. obtained by 
partitioning the TLE with water) obtained from different cells and tissues such as mixed glial cells, wild 
type mouse brain and hemibrain, ASMKO mouse brain, rHIgM22 positive OPC, mouse myelin, CST (+/-) 
and (-/-) hemibrain, and rat microglia. For each A.Ph. amounts equivalent to 150 μg protein were loaded on 
the plate, while for each pure lipid 3 nmol were loaded. After chromatographic separation (solvent system: 
CHCl3:CH3OH:CaCl2 50:42:11), After chromatographic separation, TLC plates were fixed with a 
polyisobuthylmethacrylate solution and immunostained with 5.0 μg/mL of the two primary antibody 
rHIgM22 and Human IgM (negative control) as described in “Methods”.  
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Mass spectrometry analysis  
To confirm the identification of phosphatidylinositol and phosphatidylserine species aqueous phase 
from mouse brain was purified using column chromatography (Fig. 34), as described in Materials 
and Methods. Following the column chromatographic separation, the fractions enriched in 
phosphatidylinositol and phosphatidylserine species were analyzed by ESI mass spectrometry in 
negative mode (the specific conditions are reported in the section Materials and Methods).  
The MS spectrum of the fraction enriched in phosphatidylinositol revealed the presence of one ion 
with an m/z of 885 and its MS/MS spectra, obtained by the fragmentation of the 885 ion, shows 
ions with an m/z of 581 and 419. These spectrum features are characteristic of Phosphatidylinositol 
with C18:0 and C20:4 (Fig. 35). The MS spectrum of the fraction enriched in phosphatidylserine 
revealed the presence of two ions with an m/z of 788 and 834. The MS/MS spectra obtained by the 
fragmentation of the 788 ion, shows ions with an m/z of 701 and 419 and MS/MS spectra obtained 
by the fragmentation of the 834 ion, shows ions with an m/z of 747 and 419. These spectrum 
features are characteristic of phosphatidylserine with C18:0 and C20:4 for 788 ion and 
phosphatidylserine with C18:0 and C22:6 for 834 ion (Fig. 36). The presence of five hydroxyl 
groups in inositol, the polar head of phosphatidylinositol, and the presence of α-amino group and 
one hydroxyl group in serine, the polar head of phosphatidylserine, could justify the small 
contamination of these two lipids in the aqueous phase. 
In order to better understand the characteristics of rHIgM22 binding, also fractions enriched in 
sulfatide species were analyzed by ESI mass spectrometry in negative mode (Fig. 37). The MS 
spectrum of these fraction revealed the presence of different ions: 
• 806 ion; this spectrum feature is characteristic of Sulfatide C18:0 FA 
• 850 ion; this spectrum feature is characteristic of Sulfatide C20:0 OH FA 
• 866 ion; this spectrum feature is characteristic of Sulfatide C23:0 OH FA or C22:1 2OH 
• 878 ion; this spectrum feature is characteristic of Sulfatide C22:0 OH FA 
• 904 ion; this spectrum feature is characteristic of Sulfatide C24:1 OH FA 
 
The data collected from fractions enriched in sulfatide, show that rHIgM22 can bind different 
sulfated species, with a wide variety of acyl chains of different lengths and degree of hydroxylation.  
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Figure 34 Thin layer chromatography (TLC) of column fractions. After column chromatography 
separation of aqueous phases from mouse brain, the fraction were separated by TLC using 
CHCl3:CH3OH:CH3CH(OH)CH3:H2O 70:20:5:3 (v/v/v/v) as solvent system and the chemical detection of 
lipid was carried out with Anisaldehyde reagent. 
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Figure 35. ESI-MS analysis of phosphatidylinositol.  After column chromatography separation of 
aqueous phases from mouse brain, the fractions enriched in phosphatidylinositol were subjected to ESI MS 
analysis and subsequently to ESI MS/MS.  
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Figure 36. ESI-MS analysis of phosphatidylserine species.  After column chromatography separation of 
aqueous phases from mouse brain, the fractions enriched in phosphatidylserine species were subjected to 
ESI MS analysis and subsequently to ESI MS/MS. 
 84 
 
Figure 37. ESI-MS analysis of sulfatide species.  After column chromatography separation of aqueous 
phases from mouse brain, the fractions enriched in sulfatide species were subjected to ESI MS analysis and 
subsequently to ESI MS/MS.  
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CONCLUSIONS    
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Multiple sclerosis (MS) is the most common demyelinating disease of the central 
nervous system. MS is an autoimmune disease, characterized by immune-
mediated myelin damage eventually resulting in axonal loss attributable to the 
absence of myelin sheaths [179]. T cell subsets (Th1, Th2, Th17, CD8+, NKT, 
CD4+CD25+ T regulatory cells) and B cells are involved in this disorder, thus 
the currently available MS therapies are predominantly immune-modulating and 
are aimed at reducing the number and rate of lesion formation but do not directly 
promote repair. The stimulation of remyelination, which allows to repair the 
damaged regions of the central nervous system, is a new and promising potential 
approach to treating MS.  
In adult human brain, the normal response to demyelination is spontaneous 
remyelination involving the generation of new oligodendrocytes. The myelin 
sheaths that are generated in remyelination are typically thinner and shorter than 
those generated during developmental myelination; nevertheless, they are 
associated with recovery of function [272, 273].  
In some circumstances, however, and notably in MS, remyelination occurs but 
becomes increasingly incomplete/inadequate and eventually fails, leaving the 
axons and even the entire neuron vulnerable to degeneration, that largely 
accounts for the progressive clinical decline associated with this disease [199].  
The normal adult white matter contains astrocytes, microglia and OPCs, in 
addition to myelinating oligodendrocytes [274]. Following demyelination, 
characterized by loss of oligodendrocytes and myelin, the microglia and 
astrocytes become activated [275]; the result is the activation of any OPCs [276], 
in the vicinity, which respond to mitogens and pro-migratory factors that are 
generated predominantly by reactive astrocytes and inflammatory cells [277].  
The activated OPCs proliferate and migrate in the demyelinated area becoming 
populated by an abundance of OPCs [200]. Macrophages are also recruited and 
start to remove the myelin debris [278], a process essential for the generation of 
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new myelin. In the final phase of remyelination, the recruited OPCs differentiate 
into mature oligodendrocytes with the formation of a novel myelin sheath [199].  
There are a multitude of hypotheses as to why remyelination fails in MS, which 
may reflect either changes in environmental inputs or intrinsic pathways 
regulating OPCs functions [279, 280]. Theoretically remyelination can be 
blocked at any point in the remyelination process: oligodendrocyte recruitment, 
survival, proliferation, migration, maturation, and/or myelin sheath formation. 
In late stage MS, oligodendrocyte recruitment is deficient (which could be a 
product of impaired survival, proliferation, and/or migration of 
oligodendrocytes) and appears to be the primary reason for poor remyelination 
[204]; in this case, therapeutic targets should be recruitment factors and not 
differentiation factors, which would inhibit remyelination. Otherwise, in lesions 
containing more oligodendrocytes, remyelination could fail due to an irregular 
differentiation, in which case differentiation promoters are desired and 
recruitment promoters would counteract remyelination. In addition, the formed 
glial scars, the glia-secreted factors and the presence of myelin-associated debris 
within the lesion may inhibit OPCs migration into the scar and subsequent 
differentiation. Experimental and clinical data suggest that differentiation is the 
most vulnerable phase of remyelination, and it is during this phase that 
remyelination generally fails [199].  
The strategies that are currently being developed to increase efficiency of 
remyelination can be divide in three groups: 1) cell transplant, involving the 
transplantation of myelination-competent cells directly into lesion sites [281, 
282]; 2) promotion of repair by the resident CNS stem- and precursor-cell 
populations, through the administration of growth, trophic, and neuroprotective 
factors [283]; 3) use of CNS reactive antibodies to induce remyelination [227]. 
One of these remyelination promoting antibodies is rHIgM22, which has 
recently been concluded a phase I clinical trial aimed to evaluate safety and 
tolerability in relapsing MS patients (ClinicalTrial.gov: NCT02398461), after 
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the first phase I clinical trial in MS patients was completed successfully 
(ClinicalTrial.gov: NCT01803867). rHIgM22, the recombinant form of an 
antibody identified from a patient with Waldenström macroglobulinemia, has 
been shown to enter the central nervous system, accumulate in the demyelinated 
lesions, and promote remyelination in mouse models of chronical demyelination 
[214, 223] and to bind selectively to myelin and to the surface of 
oligodendrocytes in vitro [214, 284].  
Despite these promising capabilities, both the signaling mechanisms stimulated 
by rHIgM22 and the antigen recognized are still unclear. Watzlawik et al. data 
suggest an rHIgM22-membrane mediated reorganization of a signaling complex 
which includes Lyn, integrin αvβ3 and PDGFαR [231, 246], which leads to 
inhibition of OPCs apoptotic pathway and differentiation and promotion of 
OPCs proliferation [219, 233].  
Data published by Rodriguez et al. demonstrated that rHIgM22 is able to bind to myelin 
and to the surface of oligodendrocytes in vitro [214, 246] and that it binds to CNS tissue 
sections with a pattern similar to that of O4, an anti-sulfatide antibody [245], suggesting 
that sulfatide could be one of the antigens recognized by this remyelination-promoting 
antibody.  
 
Starting from this observation, we have tested the binding of rHIgM22 to purified lipids 
and to lipid extracts prepared from several samples using two different experimental 
approaches: TLC immunostaining and surface plasmon resonance assays.  
The data collected show that rHIgM22 binds in vitro to sulfatide and its deacylated 
form, lysosulfatide, (Fig. 24, 26) but it does not bind to other myelin sphingolipids, 
such as galactosylceramide, lactosylceramide and sphingomyelin (Fig. 27). Moreover, 
SPR experiments (Fig. 25), where antigen presentation is more physiological respect 
to TLC immunostaining, showed that the binding of rHIgM22 to sulfatide is specific, 
suggesting that sulfatide could actually be one of the molecular targets of rHIgM22. In 
addition, SPR analysis revealed that the binding response of rHIgM22 to sulfatide is 
modulated by the presence of other lipids; while the presence of GalCer and cholesterol 
significantly reduce the binding of rHIgM22 to sulfatide, the presence of 
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sphingomyelin is able to increase the binding of rHIgM22 to sulfatide (Fig. 30). 
Therefore, the addition of other membrane lipids can positively or negatively affect the 
in vitro binding of rHIgM22 to sulfatide, suggesting that, in myelin and 
oligodendrocytes, the membrane lipid microenvironment containing sulfatide might 
play a relevant role in the recognition of the antigen by rHIgM22 in intact cell 
membranes.  
Using the TLC immunostaining experimental setting, other potential lipid targets have 
been screened. rHIgM22 weakly binds also phosphatidylethanolamine (PE), 
phosphatidic acid (PA), phosphatidylserine (PS) and phosphatidyinositol (PI), but TLC 
experiments using an isotype IgM control allowed to confirm that while rHIgM22 
binding to PA, PS and PI is specific, rHIgM22 binding to PE is not. Moreover, further 
analysis, with different techniques, might be required to confirm this. In addition, this 
set of experiments revealed no significant binding of rHIgM22 to PC, the most 
abundant phospholipid in any biological membrane. 
To verify whether rHIgM22 can bind sulfatide or other lipids in myelin extracts and 
other CNS cells, the binding of rHIgM22 has been tested not only to purified lipids, but 
also to partially purified lipid extracts obtained from mice and rat brain, cerebellum, 
brain myelin, mixed glial cultures, microglial cells and cultured oligodendrocytes. In 
TLC immunostaining experiments for phospholipid-void methanolized organic phases 
(Fig. 32), it was possible clearly to detected a double band co-migrating with the 
sulfatide standard in samples from wt and ASMKO mouse brain, myelin and rHIgM22-
positive cultured oligodendrocytes. All these samples showed a weak reactivity with 
the control IgM, however the ratio of the rHIgM22 signal and the control IgM signal 
was comparable to that observed for pure sulfatide. 
In TLC immunostaining experiments for aqueous phases (Fig. 33), we observed 
rHIgM22-immunoreactive bands co-migrating with the pure sulfatide standard and, 
unexpectedly, a second rHIgM22-immunoreactive band migrating below sulfated, co-
migrating with the pure PI and PS standard, confirming the previously observation 
that the antibody is able to bind sulfatide, PI and PS. In order to better understand the 
characteristics of these two glycerophospholipids, (Fig. 34), they were partially 
purified and were analyzed by ESI mass spectrometry. The results obtained led to 
hypothesize that the unknown antigens could be phosphatidylinositol (18:0/20:4-PI) 
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and two different phosphatidylserine species, 18:0/22:6-PS and 18:0/18:1-PS (Fig. 
35, 36). In addition, MS analysis for the fractions enriched in sulfatide (Fig. 37), 
shows that rHIgM22 can bind different sulfated species, with a wide variety of acyl 
chains of different lengths and degree of hydroxylation, suggesting that this binding 
is not fatty acid species-specific for the sulfatide (in agreement with the observation 
that the antibody is as well able to bind to lysosulfatide). This point of view is 
supported by the fact that only the hydrophilic carbohydrate moiety of the 
sphingolipids is exposed to the cell surface and, therefore, detectable by antibody. 
This emphasizes the carbohydrate moiety and neglects the lipid backbone as the 
essential part of the antigen.  
 
The data collected in our laboratories demonstrate that rHIgM22 binds to sulfatide in 
vitro, according to the observation that rHIgM22 is able to bind to myelin and to 
oligodendrocytes, and that its binding is abolished in CNS tissue from CST(-/-) mice, 
which lacking sulfatide. The binding to sulfatide is specific, even if the binding affinity 
is low, and can be modulated by the presence of other lipids. This confirm the 
hypothesis that there may be a possible role of the membrane microenvironment in the 
recognition of the antigen by rHIgM22. Likely, the binding of rHIgM22 to the cells 
could require a complex molecular arrangement, and, in particular, sulfatide might be 
part of the functional rHIgM22 antigen localized at the cell surface. 
In addition, rHIgM22 also reacts with phosphatidic acid, phosphatidylserine and 
phosphatidylinositol present in lipid extracts from various sources, including CST 
knock-out mice brains, MGC, and isolated astrocytes and microglia. This suggests that 
not only sulfatide, but also other membrane lipids might play a role in the binding of 
rHIgM22 to oligodendrocytes and suggests an involvement of other cell types. Indeed, 
as reported in literature, activation and proliferation of astrocytes and microglia (that is 
present in mixed glial cells too) is observed in demyelinating lesions, suggesting that 
immune response might be important in both oligodendrocyte injury and axonal 
degeneration [285]. In MS astrocytes promote the degeneration of myelin, but at the 
same time, create a permissive environment promoting remyelination through the 
secretion of molecules like cytokines [286]. In addition, data in literature show that 
rHIgM22 induced OPC proliferation in mixed glial cultures, but not in isolated OPC. 
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This suggest that the stimulation of OPC proliferation requires factors produced by 
astrocytes and/or microglia [233]. 
So, our hypothesis is that rHIgM22 does not activate myelination only binding to 
OPCs, but it also recruits in some way other cell types within the lesion niche to exert 
its function. An interaction between OPCs, astrocytes and microglia is necessary to the 
process of remyelination. This is an important step to understand the process of 
remyelination in general, however, other experiments are necessary to go deeper in the 
comprehension. Although rHIgM22 antigens seem to be identified, the molecular 
process and pathways activated are still not clear. However, we hypothesize that 
rHIgM22 needs to bind sulfatide in a particular membrane environment containing 
these lipid antigens, probably a lipid rafts organization. On the other hand, lipid rafts 
not containing sulfatide might represent the target of the antibody in cell population not 
expressing significant amounts of sulfatide, such as astrocytes and microglia. 
The identification of the binding targets of rHIgM22, the characterization of their 
membrane microenvironment and the identity of the cell types involved could 
significantly contribute to understand the signaling mechanisms underlying the 
biological activity of rHIgM22. This, in turn, would allow to obtain a better 
comprehension of the process of (re)myelination, and of the molecular mechanism 
involved in the pathophysiology of multiple sclerosis, thus allowing to define new 
potential therapeutic targets.  
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